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Abstract
The extracellular matrix (ECM) is constantly remodelled in healthy tissues; this is 
essential in normal physiological processes such as wound healing. Remodelling is 
regulated by the balanced activities of proteases and their inhibitors. An imbalance in 
activity can result in pathology such as fibrosis and cancer.
The proteases mainly responsible for breakdown of the ECM are the matrix 
metalloproteinases (MMPs). They are important for normal maintenance of the 
ECM, but also have roles in pathophysiology.
The tissue inhibitors of matrix metalloproteinases (TIMPs) are the main specific 
inhibitors of MMP activity. There are 4 identified human TIMPs, TIMP 1-4. 
Interestingly, TIMPs have roles that are independent of MMP inhibition, such as 
promoting cell proliferation and migration. Increased levels of TIMPs have been 
found in several types of cancers, including gastric cancer.
It has been found in our laboratory and by others that certain stimuli, such as 
Helicobacter pylori infection, and the gastric hormone gastrin, increase the 
expression of MMPs in the gastric epithelium, which is associated with pathology 
including the development of gastric carcinoma. The aim of this work was to 
investigate the regulation of TIMPs in the gastric epithelium.
H. pylori infection caused upregulation of TIMP-1, 3 and 4 in human gastric biopsy 
samples. Similar results were obtained in mice infected with H. felis. Increased 
expression was also seen in gastric biopsies from patients with pathologically 
elevated circulating gastrin concentrations.
TIMP 1 and 3 are expressed both in epithelial cells and in gastric myofibroblasts, 
TIMP-4 expression was restricted to epithelial cells. TIMP-1, 3 and 4 are also 
expressed in the gastric cancer cell line, AGS-Gr. Stimulation with gastrin or EGF 
increased expression of TIMP-1, 3 and 4 luciferase-reporter constructs in AGS-Gr 
cells. Inhibiting MEK1/2 markedly reduced, and inhibiting PKC partially inhibited 
the gastrin response of the TIMP-3-luc construct.
Stimulation of AGS-Gr cells with G17 also induced c-fos expression, and co­
transfection of AGS-Gr cells with TIMP-3-luc and c-fos resulted in increased 
luciferase activity to a comparable level to that seen with G17 stimulation.
xiv
TIMP-3 also inhibited gastrin-induced migration of AGS-Gr cells.
In conclusion, I have shown that TIMP expression is affected by Helicobacter 
infection and elevated gastrin, TIMPs are expressed in a cell specific manner, and 
TIMP-3 expression is induced in AGS-Gr cells by activation of the MAPK pathway 
via API. The results suggest that TIMPs have an important role in gastric 
remodelling during both health and disease.
xv
Chapter 1
Introduction
Chapter 1 - Introduction
1.1 Epithelial organisation in the stomach
The human gastric mucosa consists of a complex epithelium, lamina propria and a 
thin layer of smooth muscle called the muscularis mucosa. The epithelium is folded 
into tubular gastric glands that extend into the muscularis mucosa. The glands are 
divided into isthmus, neck and base regions, and contain a variety of different 
specialised cell types, that exist in characteristic locations. Surface mucus and mucus 
neck cells are typically present in the isthmus and neck region of the gland. Acid 
secreting parietal cells are mostly found in the neck region, and histamine producing 
enterochromaffin-like (ECL) cells, gastrin producing G-cells, somatostatin 
producing D-cells and pepsinogen secreting chief cells are found towards the base of 
the gland (Fig 1).
Parietal and ECL cells exist mainly in glands located in the corpus of the stomach, 
while the glands in the antrum contain more G-cells, D-cells and mucus cells.
The cells of the gastric glands all originate from a single pool of progenitor cells 
located in the neck region of the gland, these cells migrate upwards and downwards 
along the gland.
1
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Isthmus
Neck
Base
Fig 1: Representation of a gastric gland showing locations of cells. Glands in the 
corpus region of the stomach would normally contain parietal, EC1 and chief cells, 
while glands in the antrum contain G-cells and pepsinogen containing cells, parietal 
cells are rarely found in the antrum.
1.2 Gastrin
It has long been established that food stimulates the secretion of gastric acid in the 
stomach (Beaumont 1833). It was thought that nervous mechanisms were 
responsible for this until the discovery of the hormone secretin, which stimulates 
pancreatic secretion, by Bayliss and Starling in 1902. This invited the question of 
whether gastric acid secretion could also be controlled by a hormonal mechanism.
2
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Gastrin was discovered in 1905, and was shown to directly stimulate gastric acid 
secretion (Edkins 1905). Gastrin was isolated from gastric antrum and characterised 
by Gregory and Tracy (1964), who showed that the gastrins were 17 and 34 amino 
acid C-terminal amidated peptides, which they described as G17 and G34.
The gastrin precursor, preprogastrin is cleaved to give progastrin. Progastrin is 
cleaved by subtilisin-like prohormone convertases and carboxypeptidase E, 
generating COOH-terminal Gly-gastrins (G34-Gly and G17-Gly). These “non- 
classical gastrins” are converted to the corresponding COOH-terminally amidated 
peptides (G34 and G17), known as “classical gastrins” (Dockray 2004).
1.2.1 Actions of Gastrin
It is well-established that gastrin, released from antral G-cells, mediates increased 
gastric acid secretion after food intake (Walsh 1994). Gastrin acts via the CCK2 
receptor (CCK2R) (Dufrense et al. 2006) which is mainly located on the parietal and 
ECL cells in the gastric epithelium (Kopin et al. 1992, Dockray et al. 2005). Gastrin 
acts by stimulating ECL cells to release histamine, this then acts as a paracrine 
mediator stimulating parietal cells to release acid. As acid concentrations increase, 
there is feedback on antral D-cells resulting in the release of somatostatin, thus 
inhibiting gastrin release, as shown in Fig 2. (Hersey and Sachs 1995, Dockray et al. 
2001).
Gastrin also has a role in regulating ECL cell numbers, and regulates the expression 
of ECL genes such as histidine decarboxylase (HDC) and vesicular monoamine
3
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transporter type 2 (VMAT-2), which are responsible for histamine synthesis and 
storage (Dockray et al. 2001).
Antrum Corpus
Food
gastrin in response to food intake, gastrin causes ECL cells to release histamine which 
stimulates acid secretion from parietal cells, this feeds back on D-cells which release 
somatostatin to inhibit further gastrin release.
Elevated gastrin can stimulate the proliferation of gastric epithelial cells, and 
increase the numbers of parietal cells and ECL cells (Jensen 2002). Gastric epithelial 
progenitor cells are not thought to express the CCK2-receptor, so these responses to 
gastrin are likely to be due to the release of growth factors released by the parietal or 
ECL cells (Dockray et al. 2001).
Activation of the CCK2-receptor is linked to a wide range of biological responses 
such as stimulation of migration and invasion, and inhibition of apoptosis (Todisco
4
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et al. 2001, Wroblewski et al. 2002, Noble et al. 2003). These processes are linked to 
the oncogenic properties of gastrin.
Recent gene array studies have identified many previously unknown targets of 
gastrin, such as plasminogen activator inhibitor (PAI)-2, MMP-7 and -9 and TIMP-3 
(Varrò et al. 2002 b). This is interesting because it suggests roles for gastrin in 
epithelial organisation, in health and disease.
1.2.2 Hypergastrinaemic conditions
1.2.2.1 Gastrinoma
Gastrinomas are gastrin secreting tumours normally found in the pancreas or 
duodenum. They may be sporadic, or occur on a background of multiple endocrine 
neoplasia type-1 (MEN-1). Plasma gastrin concentration is usually elevated to the 
50-10,000pM range in gastrinoma patients (normal fasting gastrin concentration 
<50pM), and is also accompanied by high basal acid release. Approximately 30% of 
patients with gastrinoma and MEN-1 develop ECL carcinoid tumours (Gibril et al. 
2004), although in patients with sporadic gastrinoma the incidence of ECL carcinoid 
tumours is less than 1% (Peghini et al. 2002).
1.2.2.2 Achlorhydric conditions
When acid production is inhibited, circulating gastrin concentrations increase. This is 
because acid release normally inhibits G-cell function by causing D-cells to release 
somatostatin which acts as a paracrine inhibitor of G-cell function. In pernicious
5
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anaemia (PA) achlorhydria, due to loss of parietal cells, is present over many years, 
and this leads to high plasma gastrin concentrations of up to 2000pM. 5-10% of 
patients with PA develop ECL cell carcinoid tumours (Bordi et al. 1991, Bordi et al. 
1995), which in rare cases can become large and carry a significant risk of metastasis 
(Thomas et al. 1995).
1.2.2.3 Helicobacter pylori infection
Infection with the bacterium Helicobacter pylori is associated with increased plasma 
gastrin concentration (Levi et al. 1989). One of the factors causing the elevated 
gastrin is the effect of proinflammatory cytokines acting directly on the G-cells, and 
possibly on the D-cells to inhibit somatostatin release, which also contributes to 
elevated gastrin. Helicobacter pylori produces ammonia and this results in a local 
increase in pH, which also reduces somatostatin release by the D-cells (Calam et al. 
1997).
When Helicobacter pylori infection is present in the antrum only, increased gastrin 
secretion leads to increased acid production, often resulting in peptic ulcers (Calam 
et al. 1997). When the infection is present in both the antrum and corpus, 
inflammation can lead to atrophic gastritis, which is linked to a further increase in 
plasma gastrin concentration due to reduced acid inhibition of gastrin release by the 
G-cells (McColl et al. 2000). (See also section 1.4.1).
6
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1.2.3 Ins-GAS mice
Ins-GAS mice are an animal model of hypergastrinaemia. They contain a transgene 
in which a rat insulin promoter drives a human gastrin minigene to produce amidated 
gastrin in pancreatic P-cells. The mice have raised plasma gastrin concentrations. 
They show increased proliferation in the gastric mucosa and, after 4 months of age, 
loss of parietal cells with subsequent decrease in acid secretion. The mice develop 
hyperplasia, similar to that seen in humans with chronic atrophic gastritis. Older 
mice have an increased tendency to develop gastric cancer. The mice can be infected 
with Helicobacter, and this increases the rate of development of gastric cancer 
(Wang et al. 1996, Wang et al. 2000).
1.2.4 AGS cells
AGS cells are a human gastric cancer cell line, that do not express the gastrin-CCK2 
receptor. AGS-Gr cells are AGS cells stably transfected with a vector encoding the 
human CCK2R and thus respond to gastrin (Watson et al. 2001). Gastrin upregulates 
expression of many genes in this cell line, for example plasminogen activator 
inhibitor (PAI)-2 and TIMP-3 (Varro et al. 2002).
1.2.5 Gene expression regulatedby gastrin
Amidated gastrins can increase the expression of many growth factors such as TGF- 
a, HB-EGF and amphiregulin (Tsutsui et al. 1997), and in Ins-GAS mice expression 
of TGF-a and HB-EGF in the stomach are increased (Wang et al. 2000).
7
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Parietal cells can release HB-EGF in the stomach, and it is thought that gastrin leads 
to EGFR mediated autocrine inhibition of parietal cell proliferation and paracrine 
inhibition of mucous cell numbers, thus controlling cell numbers and development in 
the gastric gland (Wang et al. 2000).
Gastrin can also affect the expression of Reg in the gastric mucosa. Regia is 
expressed in ECL and chief cells in the human stomach, and mutations of Regia are 
often present in ECL carcinoid tumours, suggesting a role for Regia as a tumour 
suppressor (Higham et al. 1999).
1.3 Extracellular Protease systems
The breakdown of the extracellular matrix (ECM) is an essential part of many 
normal processes such as embryonic development, morphogenesis, reproduction and 
tissue remodelling. This is also important in disease conditions such as gastric ulcer, 
inflammatory diseases and also cancer, where processes such as local invasion, 
angiogenesis and vascular invasion all contribute to disease progression (Nagase and 
Woessner 1999, Sternlicht and Werb 2001).
8
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1.3.1 Matrix metalloproteinases (MMPs)
The proteinases mainly responsible for the breakdown of the ECM are the matrix 
metalloproteinases (MMPs). The MMPs are a zinc-dependent family of at least 23 
extracellular proteinases capable of degrading the structural proteins of the ECM and 
are involved in remodelling of the extracellular matrix. MMPs are crucial in several 
physiological processes such as embryonic development, tissue morphogenesis and 
wound healing (Stemlicht and Werb 2001), moreover levels of MMPs are often 
increased in disease. MMP overexpression is linked to matrix degradation in 
emphysema, aortic aneurysms, and many inflammatory conditions (Ashworth et al. 
1999, Curci et al. 1998, McCawley and Matrisian 2001).
There is also extensive evidence that MMPs contribute to cancer development, the 
role of MMPs in cancer was recognised in the early 1980s with the realisation that 
proteolysis was essential for tumour invasion, and the discovery of a type IV 
collagenase involved in melanoma invasion and metastasis (Liotta et al. 1980). 
MMPs are normally expressed by stromal cells, rather than the tumour cells 
themselves. MMP expression by stromal cells such as connective tissue cells, 
including fibroblasts and inflammatory cells, is thought to be induced in response to 
the tumour cells (Basset et al. 1990, Nabeshima et al 1991). MMPs contribute to 
cancer progression by altering the extracellular environment. In order for tumours to 
become invasive and metastasise they must be able to first break through the 
basement membrane, invade through local connective tissue and metastasise to 
distant organs (Kleiner 1999). MMPs are important in this process of malignancy as 
they break down the ECM, allowing invasion and thus spread of cancer cells 
throughout the body (Stemlicht and Werb 2001). They can also contribute to tumour
9
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progression by promoting invasion, angiogenesis and metastasis (Powell et al. 1993, 
Kim et al. 1998, Itoh et al. 1998, Zhai et al. 2005).
MMPs are implicated in the progression of oral squamous cell carcinoma, colorectal 
cancer, gastric cancer, ovarian cancer and cervical cancer, to name a few, with 
overexpression often indicating a worse prognosis (Baker et al. 2005, Islekel et al. 
2007, Kitoh et al. 2004, Kenny et al. 2008, Zhai et al. 2005).
Increased expression of MMP-9 enhances invasion of the ECM by AGS cells, a 
human gastric cancer cell line. Also increased expression of MMP-9 was found in 
the stomach and ECL carcinoid tumours of patients with elevated gastrin 
concentrations (Wroblewski et al. 2002).
1.3.1.1 Regulation of MMPs
It is important that the activity of MMPs is tightly controlled, because of their 
activity in breaking down the ECM, and the danger that unregulated digestion can 
destroy tissues. The MMPs are regulated in several ways. Most MMPs are secreted 
from the cell as inactive proforms, and their activation is an important step in 
regulating MMP activity outside the cell (Kleiner 1999). The expression of MMP 
mRNA is tightly controlled, individual MMPs are expressed by specific cell types, at 
low levels, and expression increases only in situations where MMP activity is 
required such as inflammation and wound healing (Coussens et al. 2001).
The main specific inhibitors of MMP activity are the tissue inhibitors of matrix 
metalloprotinases (TIMPs).
10
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1.3.2 Tissue inhibitors of matrix metalloprotinases (TIMPs)
Four homologous human TIMPs have been identified, TIMPs 1-4. The TIMPs 
inhibit MMPs through the formation of reversible 1:1 stoichiometric complexes, 
which are resistant to heat denaturation and proteolytic degradation (Gomez et al. 
1997).
The TIMPs are small proteins, about 21-28KDa in size. They have similar amino 
acid sequences, a conserved gene structure and 12 conserved cysteine residues 
forming 6 disulfide bridges, folding the protein into an N terminal and C terminal 
domain. The N terminal domain of the TIMPs is the most highly conserved between 
the four, and it is this part that is responsible for MMP inhibition (Caterina et al. 
1997), the C terminal domain is more likely to mediate effects independent of MMP 
inhibition (Chirco et al. 2006).
Unlike the MMPs, the TIMPs are all secreted from the cell in an active form 
(Sternlicht and Werb 2001). All the TIMPs have similar activities in binding to 
MMPs, however they do differ in their affinities to the various MMPs. TIMP-1 
preferentially binds to MMPs 1, 3 and 9, TIMP-2 to MMP-2, TIMP-3 to MMP-2 and 
-9, and no specific inhibition has yet been discovered for TIMP-4 (Lambert et al. 
2004). The TIMPs also differ in their abilities to bind to the inactive proMMPs, for 
example TIMP-3 will bind to proMMP-2 and -9 and TIMP-2 and -4 will bind 
proMMP-2. TIMP-2 and -3 have also been found to bind membrane type MMPs, 
while the other TIMPs do not (Lambert et al. 2004).
TIMP-3 is unique in that it is the only TIMP able to bind to the ECM. It was first 
discovered as an ECM bound molecule in chick embryo fibroblasts undergoing 
transformation (Blenis and Hawkes 1984). TIMP-3 binds to the ECM by association
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between its N-terminal domain and heparan sulphate and chondroitin sulphate chains 
of proteoglycans on the cell surface (Yu et al. 2000). Here it can regulate movement 
through the basement membrane and stroma.
TIMP-1 and -3 inhibit the ADAMs (A Disintegrin and A Metalloproteinase domain) 
and the ADAMTSs (ADAM with Thrombospondin like repeats), as well as the 
MMPs. TIMP-1 inhibits ADAM-10 and TIMP-3 inhibits ADAMs 12, 17, 19, 10, and 
ADAMTs 4 and 5 (Amour et al. 2000, Baker et al. 2002, Kashiwagi et al. 2001).
The TIMPs are expressed by many cell types, although at low levels in normal 
tissues (Lambert et al. 2004), TIMP-2 expression is constitutive and widely 
expressed throughout the body, while the expression of TIMP-1, -3 and -4 is 
inducible and more tissue specific. TIMP-1 is expressed highly in the reproductive 
organs, TIMP-3 in the heart, kidney and thymus, and TIMP-4 in the brain, heart, 
ovary and skeletal muscle (Leco et al. 1997).
It is thought that TIMPs have roles in the activation of some MMPs, for example, 
formation of a complex between MT1-MMP, proMMP-2 and TIMP-2 is essential for 
proMMP-2 activation by MT1-MMP on the cell surface (Itoh et al. 2006).
In normal tissues the TIMPs and MMPs exist in a delicate balance and the digestion 
of the ECM is tightly regulated (Woessner 2001). As a simple model, it is thought 
that as the ratio of active MMPs to TIMPs increases, there is a destruction of the 
tissues and tumour cells have an increased metastatic potential (Kleiner 1999). An 
increase in active MMP production often occurs simultaneously with increased 
TIMP expression; however MMPs must be produced in excess of TIMPs in order to 
be able to degrade the ECM (Bergin et al. 2004).
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In addition to their roles in the inhibition of MMPs, TIMPs have other various 
biological activities, independent of their MMP inhibitory activity (Sternlicht and 
Werb 2001). TIMP-1 was first identified as an erythroid potentiating protein, and as 
a protein involved in stimulating the growth of some cell lines (Gasson et al. 1985, 
Bertaux et al. 1991). It has also been found that TIMP-2 has erythroid potentiating 
activity, and stimulates the growth of lymphoma cells (Stetler-Stevenson et al. 1992, 
Hayakawa et al. 1994).
TIMPs that are mutated and lack MMP inhibitory activity have been shown to retain 
their growth promoting activity (Hayakawa et al. 1994, Wingfield et al. 1999). Also 
synthetic MMP inhibitors do not always abolish the effect of TIMPs on processes 
such as growth promotion, suggesting roles for TIMPs in these processes that are 
unrelated to MMP inhibition (Guedez et al. 1998).
NMR and crystallography studies of TIMP-1 have shown that it’s MMP inhibitory 
and growth promoting activities are physically and functionally distinct (Chesler et 
al. 1995).
This could explain the paradox whereby TIMPs are often overexpressed in cancer, 
and that instead of being beneficial, this is often associated with poor prognosis 
(Guedez et al. 1998, Joo et al. 2000, Islekel et al. 2006).
Chapter 1 - Introduction
1.3.2.1 Roles independent of MMP inhibition
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TIMPs are found to be overexpressed in several diseases, and this has been linked to 
both poor or good outcomes. The different TIMPs seem to have different roles, and 
to be regulated differently in different cells. TIMPs can also have contradictory 
influences on cellular processes depending on the cell type.
TIMP-1 has been found to increase the proliferation of various tumour cells 
(Hayakawa et al. 1992). It is involved in Burkitt’s lymphoma, where is inhibits the 
apoptosis of the lymphoma cells, thus worsening prognosis (Guedez et al. 1998), 
laryngeal squamous cell carcinoma (Gorogh et al. 2006), and gastric carcinoma 
biopsies (Koyama et al. 2004, Kubben et al. 2006), where it is associated with 
reduced survival (Joo et al. 2000, Yoshikawa et al. 2001). High levels of TIMP-1 
were found in bone metastasis from breast cancer (Voorzanger-Rousselot et al. 
2006), and also in poorly differentiated colorectal cancers, suggesting a negative 
contribution of TIMP-1 in tumour differentiation and prognosis in this type of cancer 
(Islekel et al. 2006). TIMP-1 overexpression is associated with a poor prognosis in 
many other types of cancer including breast, lymphoma and non small cell lung 
cancer (Chirco et al. 2006).
Overexpression of TIMP-1 was found in fibrotic Crohn’s disease, indicating that 
TIMP-1 may play a part in the progression of this inflammatory bowel disease, 
possibly through the inhibition of MMP activity (McKaig et al. 2003).
1.3.2.2 TIMPs in disease
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TIMP-2 stimulates the invasion and metastasis of colorectal, lung and breast cancers 
(Kossakowaska et al. 1996, Porter et al. 2004), but can inhibit invasion in various 
cancer cell lines (Baker et al. 1999). However, overexpression of TIMP-2 was found 
to lower metastatic potential in oral squamous cell carcinoma (Baker et al. 2005). 
TIMP-2 stimulates apoptosis in colorectal cancer cells, smooth muscle cells and 
retinal pigmented epithelial cells, but inhibits apoptosis in other various cancer cell 
lines (Brand et al. 2000, Valente et al. 1998, Woessner 2001). TIMP-2 inhibits 
angiogenesis of endothelial cells, independent of MMP inhibition (Seo et al. 2003). 
Koyama et al. 2004 found increased expression of TIMP-2 in gastric carcinoma 
cells.
TIMP-2 has also been described as inhibiting proliferation of several cell types 
including endothelial cells, renal cancer cells and glioma cells, thus having an 
inhibitory effect on cancer progression (Murphy et al. 1993, Miyake et al. 1999, 
Bello et al. 2001).
TIMP-3 is the only TIMP directly related to a disease. Mutations of certain tyrosine 
and cysteine residues on the TIMP-3 gene are present in Sorsby’s fundus dystrophy. 
This is an autosomal dominant macular disorder that leads to progressive loss of 
sight, eventually resulting in blindness. Excessive deposition of material within 
Bruch’s membrane is thought to be a direct consequence on the influence of TEMP-3 
on the ECM (Felbor 1995).
Decreased expression of TIMP-3 was found to be associated with increased 
invasiveness in oesophageal cancer cells (Miyazaki et al. 2004).
There is evidence that TIMP-3 is involved in inducing apoptosis of smooth muscle 
cells and neuronal cells, and is involved in the progression of neurodegenerative
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diseases such as Alzheimer’s disease (Baker et al. 1998, Lee et al. 2008). TIMP-3 
overexpression is also linked to the progression of idiopathic pulmonary fibrosis 
(Garcia-Alvarez et al. 2006)
TIMP-4 inhibits proliferation of Wilm’s tumour cells (Celiker et al. 2001). Also it 
stimulates apoptosis in cardiac fibroblasts, but inhibits apoptosis in breast cancer 
(Baker et al. 2002).
Overexpression of TIMPs was found in Peyronie’s disease, a fibrotic condition of 
the tunica albuginea. TIMP protein accumulated in the fibrotic lesions, and there was 
also decreased local MMP activity (Del Carlo et al. 2008). Overexpression of TIMP - 
1 mRNA has been found in fibrotic kidneys, and TIMP-1, -2 and -4 expression was 
increased in cardiac fibrosis (Mozes et al. 1999, Seeland et al. 2002).
Increased levels of TIMP-2 and TIMP-4 have been found in gastric carcinoma 
biopsies (Koyama et al. 2004a, Kubben et al. 2006), this is associated with reduced 
survival (Joo et al. 2000, Yoshikawa et al. 2001). TIMPs can affect cell growth and 
survival of gastric cancer cells independently of their roles in MMP activation and 
inhibition (Koyama et al. 2004).
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TIMP -1,-2 and -3 null mice have been described, these are all viable and fertile. 
However TIMP-3 null mice show spontaneous lung airspace enlargement at around 
14 days after birth, and the animals usually die at about 1 year old (Leco et al. 2001). 
This is due to a disturbance of the MMP/TIMP balance, with an increase in MMP 
activity, resulting in increased turnover of collagen in the alveoli, and a reduction in 
epithelial cell proliferation (Gill et al. 2003). In normal lung development TIMP-3 
restricts MMP activity resulting in ECM cell signalling and proliferation of epithelial 
cells in the developing bronchioles (Gill et al. 2006).
TIMP-2 null mice show motor deficits and neuromuscular junction alterations 
(Jaworski et al. 2006). TIMP-1 null mice exhibit alterations in the reproductive 
system, including altered uterine morphology, increased MMP activity in the uterus 
and a reduction of reproductive lifespan in female mice (Nothnick et al. 2000, 
Nothnick et al. 2001a, Nothnick et al. 2001b).
1.3.2.3 TIMP knockout mice
1.3.2.4 Synthetic MMP inhibitors
Several synthetic MMP inhibitors have been developed, however clinical trials have 
mostly been unsuccessful. Batimastat was one of the first to be clinically tested. It 
was found to inhibit tumour growth and metastasis (Macauley et al. 1999). However 
side effects included musculoskeletal pain and inflammation. Trials with other 
synthetic inhibitors have also been disappointing due to their lack of effect on human 
cancer progression or survival rate (Brown 2000, Bramhall et al. 2001). Clinical
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trials with tanomastat in pancreatic cancer were terminated due to poorer survival 
rates in the treatment group compared to the control (Moore et al. 2001).
Batimastat treatment caused increased liver metastasis in nude mice, and liver 
specific overexpression of MMP-2 and -9, angiogenesis factors and caspase-1, even 
in tumor-free animals (Kruger et al. 2001). MMP inhibitors causing a reduction in 
plasma levels of MMP-9 in mice led to increased tumor growth and vascularisation 
(Pozzi et al. 2002).
These types of side effects need to be considered, and further development is needed 
before clinical use of synthetic MMP inhibitors.
1.4 H e lic o b a c te r  p y lo r i infection
Helicobacter pylori is a member of a family of bacteria that colonise the mammalian 
stomach, it was discovered in the human stomach in 1982 by Marshall and Warren. 
The bacterium is associated with gastritis and peptic ulcer, and a higher incidence of 
gastric cancer has been reported with H. pylori infection (Parsonnet et al. 1991, 
Forman et al. 1991, Uemura et al. 2001), The World Health Organization and the 
International Agency for Research on Cancer classified H. pylori as a class I 
carcinogen in 1994.
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Approximately 50% of the world’s population are infected with H. pylori, infection 
usually occurring during childhood, and persisting throughout life, unless treated 
(Peek and Blaser 2002).
Chronic infection with H. pylori leads to inflammation which, depending on a range 
of host and environmental factors, can progress through a well-characterised process 
of atrophy, intestinal metaplasia, dysplasia, and cancer. Development of gastric 
cancer due to H. pylori infection has been linked to genetic mutations caused by 
chronic inflammation, an increase in epithelial proliferation, and loss of specialized 
glandular cell types such as parietal and chief cells (Fox and Wang 2001).
Several studies have shown that eradication of H. pylori from the stomach reduces 
the progression of atrophic gastritis and metaplasia, lowers the rate of gastric cancer 
recurrence, and prevents or delays the development of gastric adenocarcinoma 
(Uemura et al. 1997, Correa et al. 2000, Uemura et al. 2001).
H. pylori infection can also induce gastric cancer in rodent models, for example 
following infection over 1-2 years Mongolian gerbils have a higher rate of gastric 
adenocarcinoma (Watanabe et al. 1998, Honda et al. 1998).
1.4.1 Biological effects of H. pylori infection
H. pylori has a number of biological effects that contribute to the development of 
gastric cancer. One of the main effects on the gastric epithelium is inflammation. H. 
pylori activates the pro-inflammatory enzyme cyclooxygenase (COX)-2, which 
contributes to the production of inflammatory prostaglandins (Peek and Blaser
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2002). It has been shown that co-culture of epithelial cells with H. pylori increases 
COX-2 expression in the gastric mucosa of infected individuals (Sawaoka et al. 
1998, Fu et al. 1999). Expression of COX-2 is further increased in atrophic gastritis, 
metaplasia and gastric adenocarcinoma induced by H. pylori infection (Sung et al. 
2000, Ristimaki et al. 1997).
H. pylori infection can also increase proliferation of epithelial cells. Co-culture of H. 
pylori with epithelial cells reduces the expression of cell cycle regulatory proteins 
such as p27, leading to arrest in G1 phase of the cell cycle (Shirin et al. 1999, 
Ahmed et al. 2000). Incubation of H. pylori with epithelial cells can also result in 
DNA damage through the synthesis of reactive oxygen species (Smoot et al. 2000). 
Proliferation can also be stimulated due to the host response to the H. pylori 
infection, hypergastrinaemia can result from infection, which stimulates proliferation 
of epithelial cells (see section 1.2.2.3).
H. pylori infection is associated with both increased and decreased levels of 
apoptosis in the gastric epithelium. H. py/or/stimulates gastric epithelial cell 
apoptosis in vitro (Wagner et al. 1997, Fan et al. 1998, Peek et al. 1999), possibly by 
releasing the enzyme urease, which generates ammonia (Fan et al. 2000). Two 
studies on the effect of H. pylori on apoptosis showed that isolated gastric epithelial 
cells from infected patients had lower rates of apoptosis compared to uninfected 
samples (Peek et al. 1997, Rokkas et al. 1999).
Both increased and decreased rates of apoptosis could have detrimental effects. 
Increased rates of apoptosis could accelerate the progression to atrophic gastritis, and 
increase the risk of developing gastric cancer. However decreased apoptosis can lead
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to a higher risk of mutation, predisposing to the development of cancer (Peek and 
Blaser 2002).
1.4.2 H. pylori infection and MMP/TIMP expression
Infection with H. pylori is known to increase the expression of MMPs, and this is 
significant in the remodelling process that occurs with infection, and may lead to 
gastric cancer (Wroblewski et al. 2003, Hemers et al. 2005, McCaig et al. 2006). 
The expression of MMP-1, -2, -7 and -9 has been shown to be induced in the gastric 
epithelium with H. pylori infection (Gooz et al. 2001, Wroblewski et al. 2003, Bebb 
et al. 2005, Bergin et al. 2004, Mori et al. 2003). H. Pylori induced increase in 
MMP-7 expression has a role in stimulating migration of gastric epithelial cells 
(Wroblewski et al. 2003).
Overexpression of TIMPs has been observed in gastric mucosal tissue with H. pylori 
infection (Gooz et al. 2001, Koyama 2004b, Bodger et al. 2008). However the 
literature relating to TIMP expression and H. pylori is limited.
The disruption in MMP and TIMP activity with H. pylori infection is likely to lead 
to breakdown of the extracellular matrix, increasing migration, also to the release of 
pro-inflammatory cytokines and chemokines, contributing to H. pylori induced 
inflammation (Stemlicht and Werb 2001).
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1.5 Myofibroblasts
Myofibroblasts can be simply defined as smooth-muscle like fibroblasts. They show 
several distinguishing features e.g. prominent cytoplasmic actin microfilaments, 
adherens and gap junctions, and are contractile and motile. Immunohistochemical 
characterisation of myofibroblasts is usually by expression of a-smooth muscle actin, 
vimentin and desmin (Powell et al. 1999, Powell et al. 2005), although gastric 
myofibroblasts do not normally express desmin (Wu et al. 1999).
Myofibroblasts have important roles in a number of physiological processes. By 
secreting growth factors and their receptors, they are important in organogenesis and 
morphogenesis of tissues and organs. They also play a part in inflammation, wound 
healing, and turnover of the extracellular matrix (ECM) (Powell et al. 1999, Hinz et 
al. 2007).
Myofibroblasts are also involved in pathology in a variety of different tissue types. 
Increased proliferation of myofibroblasts is involved in fibrosis in many tissues 
including kidney, heart, liver, and lung, (Powell et al. 1999, Rocha et al. 2004, 
Willis et al. 2005, Poobalarahi et al. 2006, Diaz et al. 2007, Hinz et al. 2007). 
Stromal tissue, including myofibroblasts, can make up to 60-90% of cancer tissue, 
even though the origin of the cancer is epithelial. This gives a clear indication that 
mesenchymal-epithelial interactions have an important role in the development of 
cancer (Bhowmick et al. 2004, Gallagher et al. 2005, Powell et al. 2005, Sheehan et 
al. 2007).
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Myofibroblasts are an important sub-epithelial cell type due to their ability to 
produce epithelial growth factors and their close proximity to the epithelial cells.
Previous work carried out in this laboratory has shown that H. pylori infection 
increases the production of MMP-7 by gastric epithelial cells (Wroblewski et al. 
2003). MMP-7 acts as a myofibroblast growth factor by promoting the cleavage of 
IGFBP-5, secreted by myofibroblasts, to liberate IGF-II, which stimulates gastric 
epithelial cell proliferation and myofibroblast proliferation and migration. Over time 
increased numbers of myofibroblasts can lead to hyperproliferation and increase the 
chance of developing malignant transformation (Hemers et al. 2005, McCaig et al. 
2006).
1.6 Epithelial-Mesenchymal signalling
Interactions between epithelial cells and mesenchymal cells are very important in 
maintaining normal mucosal organisation. This occurs during normal physiological 
processes such as development and wound healing, but also in pathology such as 
progression to cancer.
The microenvironment is thought to be of key importance in cancer progression. The 
extracellular matrix (ECM) is a complex structure that surrounds and supports the 
cells in all tissues of the body, and can regulate a number of cellular processes. The 
homeostasis of the microenvironment can be disrupted by epithelial-mesenchymal
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interactions resulting in alteration in the architecture of the ECM. These changes can 
contribute to disease in many systems, including tumour progression and malignancy 
(Lukashev and Werb 1998, Brittan and Wright 2002).
Epithelial and sub-epithelial cells may release growth factors, cytokines and 
extracellular proteases, such as MMPs, and protease inhibitors, as a way to 
communicate with each other, and alter the microenvironment. Mutations that alter 
the structural properties of the ECM and the function of proteases, particularly the 
MMPs family often lead to disease, suggesting that ECM organisation is important 
for its function (Werb 1997).
An example of dysfunction in this system is Helicobacter pylori infection which 
causes inflammation of the gastric mucosa, and in some patients leads to gastric 
cancer (Correa & Chen 1994), and also prolonged hypergastrinaemia in patients with 
pernicious anaemia (PA) leading to ECL cell carcinoid tumours (Bordi et al. 1995). 
Progression to cancer in both cases involves epithelial remodelling with the loss and 
proliferation of certain cell types.
It has been shown that expression of a MMP-1 transgene in mouse epithelia caused 
an upregulation of endogenous MMP-1 in fibroblasts, resulting in neoplastic lesions 
and upregulation of other MMPs and ECM components (Thomasset et al. 1998). 
Also, results from our laboratory have shown that the release of MMP-7 from 
epithelial cells increases myofibroblasts numbers and stimulation of proliferation and 
migration, also MMP-7 can cause myofibroblasts to release IGF-II, which acts on 
myofibroblasts and epithelial cells, providing an example of epithelial-mesenchymal 
interactions altering the microenvironment (McCaig et al. 2006, Varro et al. 2007).
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The altered expression of MMPs and TIMPs is likely to be an important mechanism 
in epithelial-mesenchymal signalling, and investigation of their contribution to the 
development of pathology is important.
1.7 MAPK signalling pathways
Mitogen activated protein kinases (MAPKs) are important enzymes that are involved 
in cellular regulation. The enzymes connect cell-surface receptors to intercellular 
regulatory targets. MAPK activity is regulated via three tiered phosphorylation 
cascades composed of a MAPK, MAPK kinase (MAPKK, MKK or MEK) and a 
MEK kinase (MAPKKK or MEKK) (English et al. 1999).
MAPKs have roles in most cellular processes e.g. embryogenesis, cell 
differentiation, cell proliferation and cell death. They are activated in the cytoplasm 
and translocate to the nucleus, directly or indirectly, through downstream kinases 
(Hazzalin and Mahadevan 2002).
In mammals there are four groups of MAPKs; the extracellular signal-related kinases 
(ERK)-l and -2, Jun amino-terminal kinases (JNK)-l, -2 and -3, p38 proteins and 
ERK5. These are activated by specific MAPKs, ERK1/2 by MEK 1/2, p38 by 
MKK3/6, JNKs by MKK4/7 and ERK5 by MEK5 (Chang and Karin 2001).
Several diverse cellular processes are controlled by MAPKs, in response to several 
different extracellular stimuli, and MAPKs have overlapping substrate specificities.
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It is therefore important that MAPK activation is specific, and there are several 
mechanisms to ensure this. Scaffold proteins such as JIP1, which organises JNK1/2 
and MKK7 into specific signalling cassettes, and MP1, that interacts with ERK1 and 
MEK1 to regulate ERK1 activation (Whitman et al. 1999, Schaeffer et al. 1998), are 
one mechanism of ensuring specificity. Specific MAPK activation also depends on 
sequential interactions between the members of a particular signalling cascade (Xia 
et al. 1998).
MAPKs are activated via a two-part enzyme-substrate reaction. The MAPKs 
recognise a phosphoacceptor site composed of serine or threonine followed by a 
proline. Specificity of this activation is ensured by a docking interaction with another 
site on the kinase that recognises a specific site on the substrate (Chang and Karin 
2001).
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1.7.1 ERK1/2 cascades
ERK1/2 are ubiquitously expressed proteins that can be stimulated by a wide variety 
of ligands and cellular stresses (Lewis et al. 1998), such as growth factors, cytokines, 
stresses and ligands of G protein-coupled receptors, and are responsible for 
mediating many cellular processes (Pearson et al. 2001). ERK1/2 are activated by 
MEK1/2 (Crews et al. 1992, Kosako et al. 1992). MEK1/2 are phosphorylated by 
Raf isoforms. The Raf family of protein kinases consists of A-Raf, B-Raf and c-Raf 
(Hagemann and Rapp 1999) (Fig 3).
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Fig 3 : Overview of ERK1/2 signalling cascades. In response to stimulation by a 
variety of stimuli, Ras proteins stimulate Raf which phosphorylâtes MEK 1/2. This 
activates ERK1/2 which influence gene transcription in the nucleus.
1.7.2 Functions of MAPK signalling
One of the best-studied functions of MAPK signalling cascades is regulation of gene 
expression in response to external stimuli (Treisman 1996).
Many MAPKs induce fos genes, Fos proteins then dimerise with Jun proteins 
forming the immediate early response transcription factor complex API, responsible 
for controlling the transcription of many genes (Treisman 1996), which regulate
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many biological processes like cell proliferation and differentiation (Angel et al. 
1991).
MAPKs function in the nucleus and target DNA-bound transcription factors, 
although they can also regulate gene expression via post-translational mechanisms 
involving targets in the cytoplasm. For example JNK stabilises IL-2 mRNA in 
activated T-cells (Chen et al. 2000).
MAPKs are involved in the stimulation of cell proliferation, for example by 
promoting cell-cycle progression (Palmer et al. 1998) and enhancing AP-1 activity 
(Treinies eta/. 1999).
MAPKs can control cell survival via activation of ERK1/2, or induce apoptosis via 
JNK and p38 activation (Xia et al. 1995).
1.7.3 PKC signalling
Protein kinase C (PKC) is a signalling protein that forms part of a large family of 
multiple isoforms. These are involved in multiple biological processes. PKC can 
activate the ERK signalling cascade by stimulating Raf (Mellor and Parker 1998).
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1.8 Growth factors
1.8.1 TGF-p
TGF-P is part of the TGF-P superfamily, which is composed of many cytokines 
including TGF-P, activins, inhibins, anti-mullerian hormone and myostatin.
There are three TGF-P isoforms, TGF-pi, TGF-P2 and TGF-P3, which are all highly 
similar.
TGF-P inhibits the proliferation of epithelial, endothelial and haematopoietic cells. 
However it can promote the proliferation of mesenchymal cells, and also induce the 
deposition of ECM, integrin expression, differentiation and migration. TGF-P also 
has a role in modulating the immune response (Letterio and Roberts 1998, Piek et al. 
1999).
TGF-P signals via receptor serine/threonine kinases, known as type I and II 
receptors. This then activates members of the smad family of tumour supressors 
(Heldineta/. 1997).
The biological effects of TGF-P are context-dependent, i.e. they vary with tissue type 
and signalling by other factors/pathways.
TGF-P is expressed by all immune cell lineages, including B and T cells, it 
suppresses growth, differentiation and proliferation, which controls the immune 
system, preventing inappropriate autoimmune responses (Letterio and Roberts 1998).
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TGF-p has a dual role in tumorigenesis. It is involved in inhibiting cell proliferation 
and therefore acts as a tumour suppressor in the early stages of cancer (Moustakas et 
al. 2002). However as cancer progresses cancer cells can develop resistance to the 
growth inhibitory effects of TGF-P, also cancer cells can release non-physiological 
levels of TGF-P which may affect tumour cell differentiation, and alter the 
microenvironment, thus contributing to tumour progression (Akhurst and Balmain 
1999). Overexpression of TGF-p by tumour cells can also suppress the immune 
response which also allows tumour progression, as tumour cells escape immune 
attack (de Visser and Kast 1999).
There is evidence that TGF-P can induce epithelial-mesenchymal transition (EMT), 
via Ras/MAPK, PI3K signalling pathways, and via smad and RhoA activation. This 
contributes to cancer migration and invasion (Santibanez et al. 2000, Bhowmick et 
al. 2001).
1.8.2 PDGF
PDGF was discovered in whole blood serum in the 1970s (Ross et al. 1974), and 
originally purified from human platelets (Antoniades et al. 1979).
The PDGF family consists of four polypeptide chains, the “classical” chains, PDGF- 
AA and -BB, and the more recently discovered PDGF-CC and -DD chains (Li et al. 
2000, Bergsten et al. 2001). The four different chains dimerise to form five different 
isoforms, PDGF-AA, -AB, -BB, -CC and -DD (Fredriksson et al. 2004).
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The four PDGF genes have a broad pattern of expression, being expressed in most 
human tissues, although there are variations in the expression of the four genes. 
PDGF-D shows the lowest and most restricted expression (Fredriksson et al. 2004).
PDGF was originally discovered due to its ability to promote the proliferation of 
mesenchymal cells (Heldin et al. 1985), it is now known to have other functions 
such as promoting migration and cell survival (Claesson-Welsh 1994).
PDGF can activate several signalling systems including PI3K, PKC and Ras. The 
PDGF isoforms exert their effects by activating two different receptors, PDGFRa 
and PDGFRp.
PDGF is crucial for development; in particular the development of many different 
mesenchymal cells depends on PDGFa, such as chondrocytes, lung alveolar smooth 
muscle and oligodendrocytes (Soriano 1997, Bostrom et al. 1996, Fruttiger 1999). It 
is thought that the main role of PDGFa in development is the promotion of 
proliferation of precursor populations. PDGFp stimulation is essential for the 
development of vascular smooth muscle cells and pericytes (Lindahl et al. 1997).
In adult tissues PDGF has been shown to induce angiogenesis (Battegay et al. 1994, 
Nicosia et al. 1994), and to inhibit platelet aggregation (Bryckaert et al. 1989).
PDGF has an important role in wound healing, it acts on various cell types to aid 
healing. PDGF stimulates fibroblast and smooth muscle cell proliferation, and 
chemotaxis of neutrophils and macrophages. The production of other growth factors 
by macrophages is also stimulated (Heldin and Westermark 1999). PDGF can 
stimulate the production of matrix components such as fibronectin, collagen and 
proteoglycans (Blatti et al. 1988, Canalis 1981, Schonherr et al. 1991). Is also seems
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that PDGF is important in remodelling following wound healing as it promotes the 
secretion of collagenase by fibroblasts (Bauer et al. 1985).
PDGF has a well known role in human disease, in particular many tumours express 
PDGF and its receptors, for example ovarian cancer, breast cancer, colorectal cancer, 
pancreatic cancer and gastric cancer (Apte et al. 2004, Carvalho et al. 2005, 
Sundberg et al. 1997, Ebert et al. 1995, Chung et al. 1992). PDGF overexpression is 
linked to tumour growth and progression, and is linked to poor prognosis. PDGF is 
also of importance in tumour angiogenesis.
PDGF has a role in paracrine stimulation of stromal cells. In many tumours it is 
found that tumour cells express PDGF while stromal cells express the PDGF 
receptors, showing that the tumour cells can promote stromal cell responsiveness to 
PDGF. This contributes to the formation of stroma-rich, highly vascularised tumours 
(Anan et al. 1996, Sundberg et al. 1997, Kawai et al. 1997).
PDGF expression, and PDGF receptor expression is increased in atherosclerosis, 
having involvement in the development of atherosclerotic lesions. A possible reason 
for this is low blood flow leading to increased PDGF production by endothelial cells 
(Mondy et al. 1997). The role of PDGF in these lesions may be to stimulate smooth 
muscle cells to migrate to the intima layer of the vessels and to proliferate and 
produce matrix molecules (Pompili et al. 1995).
Many human fibrotic conditions are linked to PDGF overexpression. Macrophages 
in the alveoli secrete PDGF in pulmonary fibrosis (Vignaud et al. 1991). This can 
cause proliferation of mesenchymal and epithelial cells in the lung, and the 
deposition of collagen (Yi et al. 1996).
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PDGF overexpression is involved in kidney fibrosis, causing mesangial cell 
proliferation (Isaka et al. 1993). Other fibrotic conditions also involve PDGF, for 
example Dupuytren’s contracture, rheumatoid arthritis and scleroderma (Alman et 
al. 1996, Pohlers et al. 2006, Zheng et al. 1998).
1.8.3 HGF
In the late 1980s two molecules, Scatter factor (SF), a potent motility factor (Stoker 
et al. 1987), and Hepatocyte growth factor (HGF), which was mitogenic for 
hepatocytes (Nakamura et al. 1989), were discovered independently. These were 
later found to be identical.
HGF is a large protein consisting of 6 domains, sharing similarities with 
plasminogen. HGF is synthesised as an inactive precursor (pro-HGF) which is 
converted by proteolysis into the active factor. Pro-HGF can be converted by several 
serine proteases, including plasminogen activator (uPA) (Birchmeier et al. 2003).
HGF is a multifunctional growth factor involved in cell proliferation, migration, 
differentiation and cell survival (Trusolino and Comoglio 2002).
HGF activates the oncogene c-Met. Met signalling induces proliferation and inhibits 
apoptosis in a variety of cell types. An example is the Madin-Darby canine kidney 
(MDCK) cell line which responds to HGF/Met signalling by “scattering”, i.e. 
dispersal of cell colonies, epithelial-mesenchymal transition is induced, and mobility 
is increased (Stoker et al. 1987).
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HGF is important in development and growth; it has essential roles in 
embryogenesis, such as liver development and skeletal muscle development in limb 
buds. There is also evidence that HGF is essential for placental development (Uehara 
etal. 1995, Bladt etal. 1995).
In adult tissues HGF is expressed in many tissues and is involved in physiological 
and pathological processes. HGF is upregulated after injury, suggesting a role in 
response to tissue damage (Nakamura et al. 2000, Rabkin et al. 2001). HGF also has 
an important role as a liver mitogen, enhancing liver regeneration (Michaelopoulos 
and De Frances 1997).
HGF signalling is also an important factor in cancer. HGF and/or Met are 
overexpressed by many types of cancer including thyroid, non small cell lung cancer, 
bone, renal and colorectal, overexpression is often linked to poor prognosis (Di 
Renzo et al. 1992, Olivero et al. 1996, Scotlandi et al. 1996, Natali et al. 1996 and 
Di Renzo et al. 1995).
HGF can signal via the ERK/MAPK cascade, affecting proliferation, cell-cycle 
progression, migration and invasion, and also altering the expression of extracellular 
matrix proteinases such as the MMPs. PI3K signalling can also be activated, which 
regulates cell survival (Birchmeier et al. 2003).
1.8.4 EGF
Epidermal growth factor (EGF) was originally discovered by Cohen in 1962, after it 
was found to stimulate precocious tooth eruption and eyelid opening in newborn 
mice.
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EGF is a member of the EGF family of proteins all having very similar structural and 
functional characteristics. Other members of the family include heparin-binding 
EGF-like growth factor (HB-EGF), transforming growth factor (TGF)-a, 
amphiregulin, epiregulin, epigen and betacellulin (Harris et al. 2003).
EGF acts by binding to epithelial growth factor receptor (EGFR). This receptor has 
an important role in influencing the behaviour of epithelial cells, and also tumours of 
epithelial origin. The EGFR consists of an extracellular receptor domain, a 
transmembrane region and an intracellular domain with tyrosine kinase function 
(Herbst 2004).
The EGFR is overexpressed in most human carcinomas (Salomon et al. 1995), and is 
responsible for autocrine and paracrine regulation of tumour progression. This 
overexpression has effects which include stimulation of proliferation, promotion of 
cell survival, increased invasion and metastasis (Normanno et al. 2005).
Activation of the EGFR is also important in angiogenesis, in healthy tissues and in 
cancer. EGF stimulation is thought to promote angiogenesis via stimulation of 
VEGF secretion, the main growth factor involved in angiogenesis. EGF stimulation 
promoted angiogenesis in this manner in glioma cells, gastric cancer cells and 
pancreatic cancer cells (Goldman et al. 1993, Maity et al. 2000, Akagi et al. 1003, 
Parikh et al. 2003).
Stimulation of the EGFR can exert its effects via Ras/PI3K and MAPK signalling 
pathways, which can then stimulate tumour cell migration, invasion and metastasis 
(Herbst et al. 2004).
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The EGFR can be stimulated by gastrin, and has a role in gastric cancer progression 
(See section 1.2.5).
1.9 The TIMP Promoter
Control of TIMP expression involves factors such as regulation of gene expression, 
activation of zymogens and inhibition of active enzymes by specific inhibitors. Many 
MMPs and TIMPs are transcriptionally regulated by a variety of growth factors, 
cytokines and chemokines (Baker et al. 2002, Yan and Boyd, 2007).
It is likely that TIMP genes are downstream targets of immediate-early (IE) response 
genes such as the Fos and Jun genes that make up AP-1 (Clark et al. 2008).
TIMP-2 and TIMP-3 promoters contain multiple GC boxes in their proximal 
promoters which bind Spl and Sp3. However, these genes are still regulated by other 
mechanisms, such as NFkB, which has binding sites on TIMP-2 and -4 promoters, 
and Wnt signalling pathways (Clark et al. 2008).
The TEMP-1 promoter contains an AP-1 site with a neighbouring PEA3 site, and 
these are major mediators of transcription (Logan et al. 1996, Phillips et al. 1999).
Expression of the TIMP-1 gene can be stimulated by PMA and transforming growth 
factor betal (TGF-pl). New protein synthesis is required for this induction, and the 
induction of AP-1 transcription factors closely precedes that of TIMP-1. Mutation or
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deletion of the AP-1 site on the TIMP-1 promoter reduces the PMA induced 
response of TIMP-1 promoter-reporter constructs (Young et al. 2005).
Removal of an AP-1 site on the TIMP-1 promoter causes an almost complete loss of 
activity in liver hepatic stellate cells (HSCs), indicating that upregulation of TIMP-1 
promoter activity may be at least partially controlled by an AP-1 dependent 
mechanism in these cells (Bahr et al. 1999).
Gardner et al. (2006) found that chronic downregulation of TIMP-1 promoter 
expression is regulated through multiple mechanisms, transcriptional control and 
loss of mRNA stabilization being the main contributors. This contributes to the 
progression of chronic neuroinflammation.
The TIMP-2 gene promoter contains several Spl sequences, two AP-2 sites, three 
PEA3 sites and an AP-1 site (Hammani et al. 1996).
A polymorphism which abolishes the Spl site in the TIMP-2 promoter is associated 
with COPD (Hirano et al. 2001) and breast cancer risk (Zhou et al. 2004).
The TIMP-3 gene has a TATA box and single transcription start point. The proximal 
promoter has three GC boxes, and more distally contains six AP-1 consensus 
sequences, two NFkB sites and two p53 sites (Sun et al. 1995).
Murine TIMP-3 regulation is linked to both AP-1 dependent and independent 
regulation. Mutational inactivation of an AP-1 site on the promoter abolished the 
activity of a TIMP-3 luciferase reporter construct (Kim et al. 1997).
Two different polymorphisms in the TIMP-3 promoter contribute to susceptibility to 
the chronic lung disorder pigeon breeders disease (Hill et al. 2004).
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Amongst the TIMPs, TIMP-4 displays tight tissue specificity (Leco et al. 1997). The 
TIMP-4 promoter contains an inverted CCAAT box and a Spl site. Mutation of the 
SP1 site abolishes reporter expression completely (Young et al. 2002).
The regulation of the TIMP genes is complex. They are regulated during 
development, in normal adult physiology and in disease. Control of gene expression 
at the promoter level is therefore very important, and a better understanding of this 
could offer an useful insight into a variety of biological processes.
1.10 Aims and Objectives
Objective 1:
Investigate regulation of TEMP expression in the gastric mucosa of humans and 
a mouse model of hypergastrinaemia
In all epithelial cancers, invasion of tumour cells through the basement membrane 
and local connective tissue is essential for metastasis, and MMPs have an important 
role in this process. TIMPs are the main specific inhibitors of MMP.
Previous work from our laboratory has shown increased expression of MMPs in the 
gastric mucosa of patients with elevated plasma gastrin concentrations and H. pylori 
infection (Wroblewski et al. 2002, Wroblewski et al. 2004).
Increased levels of TIMP-1, -2 and -4 have been found in gastric carcinoma biopsies 
(Koyama et al. 2004a, Kubben et al. 2006), and an association has been found 
between high TEMP levels and reduced survival in gastric cancer (Joo et al. 2000,
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Yoshikawa et al. 2001). Previously published work from our laboratory has shown 
overexpression of TIMPs in gastric corpus biopsy tissue with H. pylori infection 
(Bodger et al. 2008).
The specific aims for this section will be:
-  Investigate expression of TIMPs in transgenic mice that over express gastrin 
(Ins-GAS), and that are infected or not infected with Helicobacter felis
-  Investigate expression of TIMPs in gastric biopsy samples from patients with 
elevated gastrin associated with pernicious anaemia (PA).
The method used to determine TIMP expression will be quantitative real time PCR 
(Q-PCR).
Hypothesis: Infection with H. felis will increase the expression of some or all of the 
TIMPs in the corpus of Ins-GAS mice.
Elevated plasma gastrin will cause increased TIMP expression in corpus biopsy 
samples from PA patients.
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Objective 2:
Investigate the responsiveness of TEMP expression
Interactions between epithelial cells and mesenchymal cells are very important in 
maintaining normal mucosal organisation, however this also plays a significant part 
in pathology such as progression to cancer.
Myofibroblasts are an important sub-epithelial cell type due to their ability to 
produce epithelial growth factors and their close proximity to the epithelial cells. 
Previous work carried out in this laboratory has shown that H. pylori infection 
increases the production of MMP-7 by gastric epithelial cells, which acts as a 
myofibroblast growth factor (Wroblewski et al. 2003). Increased numbers of 
myofibroblasts can lead to hyperproliferation and increase the chance of developing 
malignant transformations (Hemers et al. 2005, McCaig et al. 2006).
The role of MMPs in epithelial-mesenchymal signalling, and in the development of 
gastric cancer, makes investigating the role of their natural inhibitors, the TIMPs, in 
these processes relevant and important.
The specific aims for this section will be:
-  Investigate the cellular expression of TIMPs in the human gastric mucosa
-  Investigate the expression and localisation of TIMPs in a gastric cancer cell 
line, AGS-Gr
-  Investigate the response of TIMP expression to growth factors and gastrin
-  Investigate the biological relevance of TIMPs through functional assays e.g. 
migration or invasion
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The main methods used in this section will be immunohistochemistry, 
Immunocytochemistry, Western blotting and migration assays.
Hypothesis: TIMP expression will be influenced by growth factors and gastrin 
stimulation. TIMPs will have an effect on cellular processes such as migration.
Objective 3:
Investigate the cellular mechanism and responsiveness to stimulation of TIMP 
expression
The expression of TEMPs in response to various conditions such as Helicobacter 
infection, elevated plasma gastrin levels and growth factor stimulation will have 
been investigated.
Dissection of the mechanism of stimulation of TEMP expression is relevant in order 
to give greater understanding into the role of TEMPs in the organisation of the gastric 
epithelium, and biological processes in normal and pathological conditions.
The specific aims of this section will be:
-  Investigate the regulation of TIMP luciferase expression in 
myofibroblasts and/or AGS-Gr cells, in response to growth factor or 
gastrin stimulation
-  Dissect signalling pathways for TIMP expression
The main methods used to achieve this will be luciferase-reporter assays in 
myofibroblasts or AGS-Gr cells transfected with TIMP-luc reporter constructs.
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2.1 Materials
Cell culture media was obtained from Sigma (Poole, UK), FBS from Hyclone 
(Cramlington, UK), antibiotic-antimycotic, penicillin/streptomycin and non-essential 
amino acid solution from Sigma. Cell culture plastic ware was obtained from 
Invitrogen (Paisley, UK). Trypsin and EDTA were obtained from Sigma.
TRI-Reagent was supplied by Sigma. DNAse and DNAse buffer, random hexamers, 
AMV-reverse transcriptase, AMV buffer and RNAsin were obtained from Promega 
(Southampton, UK). Restriction enzymes were obtained from Sigma or New 
England Biolabs (Herts, UK), restriction enzyme buffers were also from Sigma or 
NEB and BSA was obtained from Promega. DNA hyperladder 1 was from Bioline 
(London, UK). T4 DNA ligase and T4 buffer were from Promega. Klenow enzyme 
was bought from Bioline. Competent cells were obtained from Bioline.
Protein ladder was obtained from Fermentas Life Sciences (York, UK); 
nitrocellulose membrane was from Amersham Biosciences (Bucks, UK). Primary 
antibodies were obtained from RDI (Cambridge, UK), Chemicon (Herts, UK) or 
Santa-Cruz (Wembley, UK). GAPDH antibody used for Western blotting was from 
Biodesign (Abingdon, UK). Western Blot secondary antibodies were obtained from 
Sigma or Pierce (Northumberland, UK), Immunocytochemistry secondary antibodies 
were from Jackson ImmunoResearch (Suffolk, UK). Chemiluminescence substrate 
was obtained from Pierce and film was obtained from Amersham Biosciences. 
Protease inhibitor and phosphatase inhibitor were bought from Calbiochem,
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(Nottingham, UK) and RIPA buffer from Upstate (Herts, UK). Vectashield was 
obtained from Vector (Peterborough, UK).
Nucleofection solutions were obtained from Amaxa (Koln, Germany). Combi-mag 
was obtained from Oz Biosciences (Marseilles, France), TransFast transfection 
reagent was from Promega.
Renilla (ph-SV40) and pGL4 luciferase vectors were bought from Promega, and 
luciferase reporter assay kits were from Promega.
Inhibitor RO-320432 was obtained from Alexis Biochemicals, UO-126 was obtained 
from Cell Signaling Technology (Herts, UK) and LY-294002 was obtained from 
Promega.
Q-PCR primers and probes, 18s kit and master-mix were bought from Eurogentec 
(Southampton UK).
All other general chemicals and reagents were obtained from Sigma.
2.2 Cell Culture
2.2.1 Human gastric myofibroblasts
Myofibroblasts were prepared from human gastric corpus using a published method 
(Wu et al. 1999). Myofibroblasts were maintained in Dulbecco’s modified Eagle 
medium (Sigma) supplemented with 10% foetal bovine serum (Hyclone,), 2% 
antibiotic-antimycotic (Sigma), 1% penicillin/streptomycin (Sigma) and 1% non­
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essential amino acid solution (Sigma). Cells were maintained at 37°C. Medium was 
replaced every 48-60 hours. Myofibroblast identity was confirmed by positive 
staining for a-SMA and vimentin.
All work involving primary human tissue was approved by the local Ethics 
Committees; all patients gave informed written consent.
2.2.2 AGS-Gr cells
AGS-Gr cells are a human gastric cancer cell line stably transfected with a vector 
encoding the gastrin-CCK2 receptor (CCK2R) as described by Watson el al. (2001). 
AGS-Gr cells were cultured in nutrient mixture F-12 HAM (Sigma) supplemented 
with 10% foetal bovine serum (Hyclone) and 1% penicillin/streptomycin (Sigma). 
Cells were maintained at 37°C. Medium was replaced every 2-3 days.
2.3 RNA extraction
2.3.1 Tissue
50-100mg of mouse tissue was homogenised in 1ml TRI Reagent (Sigma). The 
homogenised lysate was centrifuged at 12,000g for 10 min at 4°C to remove 
insoluble material. The clear supernatant was transferred to a clean tube, allowed to 
stand at room temperature for 5 min before adding 0.2ml chloroform. The sample 
was shaken vigorously by hand for 15 s, allowed to stand for 5 min at room
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temperature, and centrifuged at 12,000g for 15 min at 4°C. After centrifugation the 
mixture separated into 3 phases, the colourless upper aqueous phase containing RNA 
was transferred to clean 1.5ml tubes, and 0.5ml isopropanol added. The sample was 
mixed and allowed to stand for 5-10 min at room temperature before centrifuging at 
12,000g for 10 min at 4°C. Centrifugation results in a precipitated RNA pellet. The 
supernatant was removed and the RNA pellet washed in 1ml ice cold 70% ethanol, 
vortexed and centrifuged at 7500g for 5 min at 4°C. The pellet was then air-dried for 
5-10 min and re-dissolved in an appropriate volume of DEPC treated water. The 
RNA concentration and purity was estimated spectrophometrically at 260 and 
280nm.
If the RNA was to be stored, following washing the RNA pellet with 70% ethanol, 
lml ice cold absolute ethanol and 20pl 3M sodium acetate (in DEPC treated water) 
were added, and this was stored at -80°C.
2.3.2 Adherent cells
Cells were grown until confluent in a 10cm culture dish, the medium discarded and 
lml TRI Reagent (Sigma) added directly onto the dish to lyse the cells. The lysate 
was passed through a pipette until homogeneous. RNA was then extracted from the 
homogenised lysate as described above. Following extraction the RNA was 
precipitated and stored under ethanol at -80°C.
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2.4 Molecular Biology
2.4.1 DNAse treating of RNA samples
In order to precipitate RNA, pellets stored in sodium acetate/ethanol were 
microfuged at max speed for 15min at 4°C, the supernatant was carefully discarded 
and the pellet briefly air dried. The dried pellet was washed in 1ml ice cold 70% 
ethanol, and again in ice cold absolute ethanol. After the final wash the pellet was air 
dried for 10-15 min before resuspending in 20-30pl DEPC water, depending on size 
of pellet, and gently shaking for 15-30 min.
The RNA concentration and purity was estimated spectrophotometrically at 260 and 
280nm.
30pg (less if amount of sample was limiting) RNA was treated with 30pl (lunit/pg 
RNA) DNAse (Promega), and 5 pi lOx DNAse buffer, made up to a total reaction 
volume of 50pl with DEPC treated water. This mixture was incubated at 37°C for 
30min. The reaction volume was increased to 200pl with DEPC-treated water and an 
equal volume of acid phenol chloroform added. The sample was vigorously mixed 
and centrifuged at max speed for 5 min. The top aqueous layer, containing the RNA, 
was removed and to this 1ml ice cold absolute ethanol and 20pl 3M sodium acetate 
(in DEPC treated water) was added. The sample was stored at -80°C and re­
precipitated when required.
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2.4.2 Reverse transcription of RNA
RNA stored under ethanol at -80°C was precipitated as described above and 
resuspended in 20-30pl DEPC water, according to pellet size. The RNA 
concentration and purity was estimated spectrophotometrically at 260 and 280nm.
In most cases 5pg of RNA was reverse transcribed, however if the amount of RNA 
present was inadequate less was used (1 pig minimum). The required volume of RNA 
(maximum 18.5pi) was pipetted into sterile tubes, and 0.5pg random hexamers 
(Promega) added and the volume increased to lOpl with DEPC treated water if 
necessary. In order to anneal the primer and RNA the sample was heated to 70°C for 
5min, and allowed to cool slowly to less than 40°C by switching off the heat block 
and leaving the tubes in place. After cooling the following reagents were added to 
the sample in the order stated; 6pl 5xAMV buffer (Promega), ImM dNTP mix (stock 
12.5mM), 20u RNAsin (Promega), and 15u AMV-RT (Promega). The reaction 
volume was increased to 30pl with sterile distilled water. The reaction mixture was 
left to proceed at room temperature for lOmin before incubation at 42°C for one 
hour. The reaction was stopped by heating to 95°C for 5 min, and the cDNA was 
stored at -20°C. Any unused RNA was re-precipitated as described above and stored 
at -80°C.
2.4.3 Restriction Enzyme Digests
In each restriction digest l-2pg purified plasmid DNA was used, with 1 unit enzyme 
per pg DNA. The final reaction volume was 25pl for single enzyme reactions, or 
30pl for double digests. The appropriate lx buffer was used, buffers were supplied at
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a lOx concentration so 2.5pl was added per 25pi digest. When required, BSA 
(Promega) was added at a final concentration of 100-200pg/ml. The reaction was 
made up to the final volume with sterile distilled water.
The digest was allowed to proceed at the optimum temperature for the enzymes used 
for 1.5-2 hours. See appendix 1 (Chapter 8.1) for enzymes used and reaction 
conditions.
2.5 Plasmid Preparation
2.5.1 Elution of DNA from agarose gel
The DNA sample (<5pg) was separated on a standard 0.8% agarose gel in TBE 
(Tris-borate/EDTA) buffer. The DNA fragment was visualised with UV light and 
excised from the agarose gel with a clean scalpel. A QIAGEN MinElute Gel 
Extraction Kit (for extraction of DNA fragments 70bp -  4Kb) was used to extract the 
DNA (Qiagen, Crawley UK).
The gel slice was weighed in a 1.5ml tube, and 3 volumes of Buffer QG (see chapter 
8.2 for compositions) were added to 1 volume of gel (100mg ~ lOOpl). The 
maximum weight of gel slice added per spin column was 400mg. The gel slice and 
buffer mixture was incubated at 50°C for 10 min, with vortexing every 2-3 min. 
After the gel slice had dissolved completely 1 gel volume of isopropanol was added 
and the sample was mixed by inverting the tube several times. A Qiagen MinElute 
column was placed in a 2ml collection tube, the sample was applied to the column
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and centrifuged for 1 min at 10,000g, in order to bind the DNA. The flow-through 
was discarded and 500pl of Buffer QG was added to the spin column which was 
centrifuged for 1 min at 10,000g. The flow-through was discarded and 750pl of 
Buffer PE was added to the column to wash the DNA, this was centrifuged for 1 min 
at 10,000g. The flow-through was discarded and the column centrifuged again for an 
additional 1 min at 10,000g. The column was placed into a clean 1.5ml 
microcentrifuge tube and to elute the DNA lOpl of Buffer EB (lOmM Tris-Cl, pH 
8.5) was pipetted into the centre of the membrane, the column left to stand for 1 min, 
and then centrifuged for 1 min at 10,000g.
2.5.2 DNA Ligation
Each ligation reaction included 50ng vector DNA with a 3:1 molar ratio of 
insert:vector DNA. Amounts of vector and insert were estimated by running on an 
agarose gel and comparing to 5pl DNA hyperladder 1 (Bioline).
To the appropriate volume of insert and vector DNA, lpl T4 DNA Ligase (Promega) 
and 1 jliI T4 lOx Buffer (Promega) were added in a total reaction volume of 
approximately lOpl (made up with sterile distilled water if necessary). This reaction 
was left to proceed at 4°C for 16-72 hours.
2.5.3 Transformation of competent cells with plasmid DNA
For transformation with purified plasmid DNA, the competent cells used were a- 
Select Chemically Competent Cells -  Silver efficiency (Bioline). For
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transformations using ligations a-Select Chemically Competent Cells -  Gold 
efficiency (Bioline) were used. The cells were stored at -80°C and prior to 
transformation were thawed on wet ice. After mixing gently 50pl competent cells 
were added to 2pi ligation or lpl plasmid DNA and this mixture was left on ice for 
20 minutes. The cells were then heat-shocked at 42°C for 45s then returned to ice for 
2 minutes. The transformation reaction was diluted by adding 1ml SOC (2% 
tryptone, 0.5% yeast extract, 0.05% NaCl, 2.5mM KC1, lOmM MgCL and 20mM 
glucose) and the tubes were shaken at 225rpm for 1 hour at 37°C. 200pl of the 
transformed cells were plated onto LB agar (1% tryptone, 0.5% yeast extract, 1% 
NaCl, 1.2% agar) plates containing appropriate selective antibiotic and incubated 
overnight at 37°C.
2.5.4 Purification of plasmid DNA
2.5.4.1 Purification of up to 500pg plasmid DNA
After transforming competent cells and growing on LB agar plates, a single colony 
was picked from the plate and a starter culture of 3ml LB medium containing the 
appropriate selective antibiotic was inoculated. This was incubated for 6-8 h at 37°C 
with shaking at 225 rpm.
lml of the 3ml starter culture was diluted in 100ml LB medium containing the 
appropriate selective antibiotic. This was grown at 37°C overnight with shaking at 
225rpm. The bacterial cells were harvested by centrifugation at 6000g for 15 min at 
4°C. A QIAGEN plasmid maxi kit was used to purify the DNA. The bacterial pellet 
was resuspended in 10ml Buffer PI (with RNaseA added to give a final
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concentration of lOOpg/ml), see Chapter 8.2 for buffer compositions. 10ml Buffer P2 
was added and the mixture was incubated at room temperature for 5 min. 10ml of 
chilled Buffer P3 was added and the mixture was mixed and incubated on ice for 20 
min. The mixture was centrifuged at 20,000g for 30 min at 4°C, the supernatant 
containing plasmid DNA was centrifuged again at 20,000g for 15 min at 4°C. While 
centrifuging a QIAGEN-tip 500 was equilibriated by applying 10ml Buffer QBT. 
The supernatant containing the plasmid DNA was applied to the QIAGEN-tip and 
after this had flowed through the tip was washed with 2 x 30ml Buffer QC. The 
plasmid DNA was eluted with 15ml Buffer QF and the DNA precipitated by adding 
10.5ml room-temperature isopropanol. This was centrifuged immediately at 15,000g 
for 30 min at 4°C. The supernatant was discarded and the DNA pellet washed with 
5ml of room-temperature 70% ethanol, and centrifuged again at 15,000g for 10 min. 
The supernatant was carefully removed and the pellet dried in a flow hood for 5-10 
min. The DNA pellet was redissolved in 500pl lOmM Tris-Cl pH 8.5. The yield was 
determined and purity estimated by spectrophotometry at 260 and 280 nm.
2.5.4.2 Purification of up to 20pg plasmid DNA
After transforming competent cells and growing on LB agar plates a single colony 
was picked from the plate and a starter culture of 3ml LB medium containing the 
appropriate selective antibiotic was inoculated. This was incubated overnight at 37°C 
with shaking at 225 rpm. A Sigma GenElute™ Plasmid Miniprep Kit was used to 
purify the plasmid DNA. The cells were pelleted by centrifugation at 12,000g for 1 
min and resuspended in 200pl resuspension solution (with RNase A added to give a 
final concentration of lOOpg/ml), see Chapter 8.2 for buffer compositions. After
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mixing, 200pl of lysis solution was added and the mixture incubated at room 
temperature for up to 5 min before adding 350pl of neutralization solution and 
inverting 4-6 times to mix. The mixture was then centrifuged at max speed for 10 
min. The cleared lysate was transferred into a Mini Spin Column in a collection tube 
and centrifuged at 12,000g for 1 min. The flow-through was discarded and 750pl 
wash solution added to the column. This was centrifuged at 12,000g for 1 min, the 
flow through was discarded and the column centrifuged again at 12,000g for 2 min 
to dry the column. The column was transferred to a new collection tube and lOOpl 
elution solution added. This was centrifuged at 12,000g for 1 min to elute the DNA. 
The yield was determined by spectrophotometry at 260 nm.
2.6 Western Blotting
2.6.1 Protein extraction from whole cells
The medium was removed from the cells and reserved for concentration (see below). 
lOpl each protease inhibitor cocktail set III and phosphatase inhibitor cocktail set II 
(Calbiochem) were added to 1ml RIPA buffer (Upstate). The cells were washed once 
with sterile lxPBS, 2ml 0.02% EDTA solution (Sigma) was then added, to detach 
the cells. 8ml full medium was then added to the cells followed by centrifugation at 
800g for 7min. The cell pellet was resuspended in 80pl RIPA buffer, sonicated for 
10min and left on ice for 30min. Cells were then centrifuged at 20,000g for 7 min at 
4°C. The supernatant, containing protein, was stored at -80°C.
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2.6.2 Concentrating conditioned medium
Medium was removed from the cells and centrifuged at 800g for 7min, to pellet any 
remaining cells or debris. The supernatant was placed into the reservoir of a medium 
concentrating column (Millipore, Watford UK) and centrifuged at 2000g for 20min. 
Flow-through was discarded and remaining medium added to the column. This was 
repeated until 1.5ml medium remained in the column reservoir. The medium was 
placed into a 15ml tube and whilst vortexing, an equal volume of ice cold 20% TCA 
was slowly added. The mixture was left on ice for 2h then centrifuged at 20,000g at 
4°C for lOmin. The protein pellet was washed twice with cold 100% ethanol and 
resuspended in a suitable volume (50-100pl) RIPA buffer, depending on the size of 
the pellet, and stored at -80°C.
2.6.3 Protein estimation
Protein estimation was carried out using a Bio-Rad DC protein assay kit (Bio-Rad, 
Herts UK). Standards of 0, 0.2, 0.5, 0.75, 1 and 1.44 mg/ml BSA, made up in RIPA 
buffer, were used to generate a standard curve. All standards and samples were 
measured in triplicate; samples were diluted 1:5 in RIPA buffer. The assay was 
carried out in a flat-bottomed 96-well plate. 5pi standard or diluted sample were 
pipetted into triplicate wells. 1ml solution A was mixed with 25pl solution S, and 
20pl dispensed to each well containing sample or standard. 200pl solution B was 
then added to each sample and the plate was left at room temperature for 15 min. If 
the samples appeared darker than the standards by eye, the assay was repeated using 
a 1:10 sample dilution. The amount of protein was measured by reading each sample
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at 750nm using a Packard SpectraCount plate reader (Packard, UK). A standard 
curve was drawn manually using the measurements from the standards, and this was 
used to calculate the amount of protein present in the samples.
2.6.4 Western Blotting
Protein lysates and media samples were separated on 12% SDS-polyacrylamide gels, 
made up using the quantities of reagents shown in table 3:
Resolving Gel 12%
Acrylamide/Bis 9.9ml
ddH20 8.375ml
1.5M Tris-HCl pH 8.8 6.25ml
10% (w/v) SDS 0.25ml
10% ammonium persulphate (fresh) 0.125ml
TEMED 0.012ml
Table 1: quantities of reagents used to make SDS-polyacrylamide gels. These 
quantities make 4 gels using 1.5mm plates.
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The gels were set for 30-40 min at room temperature; a 4% stacking gel was then 
poured (1.3ml Acrylamide/Bis, 6.1ml ddH20, 2.5ml 0.5M Tris-HCl pH 6.8, 0.1ml 
10% (w/v) SDS, 0.05ml 10% ammonium persulphate (fresh) and 0.01ml TEMED). 
Combs were inserted and the gel set for 30-40 min at room temperature.
The protein and media samples to be loaded were prepared by adding the appropriate 
volume of 6x Laemli buffer (125mM Tris-Cl pH 6.7, 6% SDS, 20% glycerol, 10% 
2-mercaptoethanol, 0.1% bromophenol blue). Before loading onto the gel each 
sample was heated to 99°C for 5 minutes. 5pi PageRuler™ Prestained Protein 
Ladder (Fermentas Life Sciences) was loaded in one lane on each gel. The proteins 
were electrophoresed at 75V for 1.5-2 hours, until the dye migration front reached 
the bottom of the gel, in 400ml lx running buffer per gel tank (5x running buffer pH 
8.3; 15g Tris base 25mM, 72g Glycine 192mM, 5g 0.1% SDS in 1L ddH20).
The proteins were then transferred onto nitrocellulose membranes (Amersham 
Biosciences), at 100V for 1 hour exactly. Tanks were filled with transfer buffer 
(11.3g Glycine, 2.4g Tris Base, 200ml Methanol in 1L ddH20). After transfer the 
membranes were blocked in 5% non-fat milk in TBS-tween (0.1%). Primary 
antibodies were added in 5ml blocking solution and membranes were incubated in 
primary antibody overnight on a rocking table at 4°C (see chapter 8.4 for details). 
Primary antibodies were followed by HRP-conjugated secondary antibodies (Pierce) 
all diluted in blocking buffer (see chapter 8.4 for dilutions). Incubation with 
secondary antibody took place on a rocking table for 1 hour at room temperature. 
Before and after addition of the secondary antibody the membrane was washed by 
adding 3x10ml TBS-tween (0.1%) for 10 min per wash. Detection was by
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SuperSignal West Pico Chemiluminescence substrate (Pierce) and Hyper Film 
(Amersham Biosciences).
Blots were re-probed with GAPDH (Biodesign) as a control for equal loading. 
Before adding the GAPDH antibody the membranes were washed 3x 10 min in TBS- 
tween (0.1%) then blocked for l-2h in 5% non-fat milk in TBS-tween (0.1%). The 
GAPDH antibody was used at a 1:10,000 dilution, probed overnight at 4°C with 
shaking. The secondary antibody used was rabbit anti-mouse (Pierce) 1:5000 
dilution in blocking buffer, this incubation took place for lh at room temperature 
with shaking.
2.8 Immunocytochemistry
Cells were seeded directly into 4-well chamber slides, in full serum medium (FSM) 
and left for at least 24h. Cells were then serum starved for 24h, washed twice in 
PBS and fixed by incubating in 500jll1 4% paraformaldehyde per well for 30 min at 
room temperature. Cells were washed twice in 1ml PBS then either stored under 
PBS at 4°C for up to 1 week, or used for immunocytochemistry immediately. To 
carry out immunocytochemistry cells were incubated in 500pi PBT (0.3% BSA, 
0.2% triton-X in PBS) for 30 min at room temperature. After incubation cells were 
washed twice in PBS and incubated in 500pl 5% BSA for 10 min at room 
temperature. Cells were washed twice in PBS and incubated in 10% donkey serum 
for 30 min at room temperature. Cells were washed twice again in PBS before 
adding the primary antibody, 200pl per well diluted in PBS in a moist environment,
56
Chapter 2 -  Materials and Methods
and incubated overnight at 4°C (see chapter 8.5 for primary antibodies used). After 
the primary antibody incubation the cells were incubated for 10 min at room 
temperature in 0.14M NaCl (in PBS) followed by an incubation in 0.5M NaCl (in 
PBS) for 10 min at room temperature, and a further incubation for 10 min in 0.14M 
NaCl (in PBS). The FITC-conjugated secondary antibodies (Jackson 
ImmunoResearch) were then added, made up in lOmM HEPES pH7.6 1:400 
dilution, and incubated at room temperature for 1 hour in the dark. Cells were then 
washed 3 times in PBS then mounted in Vectashield containing DAPI (Vector) to 
counter stain nuclei.
Slides were examined using a fluorescence microscope and images processed using 
AxioVision 4.6 imaging software (Zeiss, Welwyn Garden City, UK). Ten fields of 
three replicates were counted and results expressed as percentages of total cell 
number.
2.9 Transfection
2.9.1 Myofibroblasts
2.9.1.1 Nucleofection
Cells were grown to 80-100% confluency in T75 culture flasks, and 2ml trypsin 
added per flask to detach cells. 8ml serum free medium (SFM) was added to the 
detached cells which were counted using a haemocytometer. 0.5-lxl06 cells were 
used per nucleofection sample; these were centrifuged at 800g for 7 minutes and
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resuspended in 120pl Human AoSMC nucleofector™ solution (Amaxa) per sample 
required.
l-5pg highly purified plasmid DNA and lOpg renilla (phRL-SV40, Promega) 
reporter construct were used per transfection sample, lOOpl cell solution was added 
to the DNA. 120|j,l of this transfection mixture was pipetted into an amaxa cuvette 
and each sample was then nucleofected using amaxa Nucleofector™ machine 
program U-25. Each transfection was carried out in triplicate.
After transfection 500pl of FSM was added to the cuvette and this was transferred to 
a clean tube. The transfected cells were transferred to a 6-well plate, an equal amount 
of cells being added per well. The transfected cells were left at 37°C for 48h.
2.9.1.2 Magnetofection
Cells were grown to 80-100% confluency in T75 culture flasks. To detach cells 2ml 
trypsin was added per flask. 8ml SFM was added to detached cells which were 
counted using a haemocytometer. 100,000 cells were seeded per well of a 6-well 
plate, each well containing 2ml FSM. The plate was left at 37°C for approximately 
24h.
Cells were transfected in 0.8ml SFM per well. The transfection mixture was made up 
as a master mix, so 0.8ml per well SFM was added to a sterile tube. To this 
20ng/well Renilla and lpg/well of the required plasmid DNA was added. The 
mixture was then vortexed for 20-30s before adding lpl/pg DNA of CombiMag 
reagent (Oz Biosciences). After vortexing for 20-30s 6pl/pg TransFast™ 
transfection reagent (Promega) was added, then the mixture vortexed again for 20-
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30s. The mixture was then incubated for 20min at room temperature. After washing 
each well twice with serum free medium 0.8ml of the transfection mixture was added 
per well and plates were incubated on magnetic plates (Oz Biosciences) for 15min at 
room temperature. After this incubation 1.5ml FSM was added to each well and the 
plates were returned to a 37°C incubator, and left for approximately 48h before 
stimulation/harvesting. Each transfection was carried out in triplicate.
2.9.2 AGS-Gr cells
2.9.2.1 Nucleofection
Cells were grown in T75 culture flasks, and detached by adding 2ml trypsin per 
flask. 8ml SFM was added to the detached cells which were counted using a 
haemocytometer. The cells were then centrifuged at 800g for 7 minutes, washed with 
PBS and then centrifuged again at 800g for 7 minutes. The liquid was then drained 
from the cell pellet, which was re-suspended in 120pl cell line nucleofector solution 
(Amaxa) per sample required. The re-suspended cells were added to 1.5ml tubes 
containing the DNA/siRNA to be transfected. This was mixed by pipetting up and 
down. lOOpl of this solution was placed in a cuvette and nucleofected using amaxa 
Nucleofector™ machine program U-25. 500pi full medium was added to the 
nucleofected cells, which were transferred to a clean tube. The transfected cells were 
then placed in T25 tissue culture flasks, 10cm2 culture dishes or chamber slides as 
required.
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2.9.2.2 Lipofection
Cells were grown to 80-100% confluency in T75 culture flasks. Cells were counted 
and 250,000 cells were seeded per well of a 6-well plate, each well containing 2ml 
full medium. The plate was left at 37°C for approximately 24h.
Cells were transfected in 0.8ml SFM per well. The transfection mixture was made up 
as a master mix, so 0.8ml per well SFM was added to a sterile tube. To the SFM 
1.5ng/well Renilla and 0.2-lpg/well of the required plasmid DNA was added. The 
mixture was then vortexed for 20-30s before adding 6pl/pg TransFast™ transfection 
reagent (Promega), the mixture was then vortexed for 20-30s and incubated for 
20min at room temperature. After washing each well twice with serum free medium 
0.8ml of the transfection mixture was added per well and plates were incubated at 
37°C for 1 hour. After this incubation 2ml FSM was added to each well and the 
plates were returned to a 37°C incubator, and left for approximately 24h before 
stimulation/harvesting. Each transfection was carried out in triplicate.
2.10 Luciferase Reporter Assays
Transfected cells were stimulated in 2ml SFM after washing each well twice with 
SFM. After the last wash all traces of medium were removed with a sterile pipette. 
Stimulation took place at 37°C for 4-24h, depending on individual protocols.
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To harvest cells after stimulation, each well was washed twice with non-sterile PBS 
and 0.5ml lx Passive Lysis Buffer (Promega) was added. The plates were then either 
read immediately or stored at -80°C for up to 48h.
Luciferase assays were performed using the dual-luciferase reporter assay system 
(Promega), in a Lumat LB9507 (E G & G Berthold) luminometer. The luminometer 
was programmed to inject lOOpl of each reagent per sample, and to provide a 3s 
delay and 10s measuring period per sample. 20pl from each well was transferred to a 
plastic tube for measurement. Each well was read once.
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3.1 Introduction
The breakdown of the extracellular matrix (ECM) is an essential part of many 
normal processes in the stomach, such as development and tissue remodelling after 
injury. It is also important in pathology such as gastric ulcer, chronic inflammation 
and cancer, where processes such as local invasion, angiogenesis and vascular 
invasion all contribute to disease progression (Nagase and Woessner 1999, Stemlicht 
and Werb 2001).
As I mentioned in the introduction, the proteinases mainly responsible for the 
breakdown of the ECM are the matrix metalloproteinases (MMPs).
Increased expression of MMP-9 enhances invasion of the ECM by the human gastric 
cancer cell line, AGS. Also, increased expression of MMP-9 was found in the gastric 
mucosa and ECL carcinoid tumours of patients with elevated gastrin concentrations 
(Wroblewski et al. 2002). It is known that H. pylori infection in the stomach 
predisposes some patients to gastric cancer (Uemura et al. 2001), and MMP-7 may 
have a role in the response of gastric epithelial cells to H. pylori infection and 
progression to cancer. Indeed H. pylori infection is associated with increased MMP- 
7 expression in gastric epithelial cells, and this has a role in stimulating their 
migration (Wroblewski et al. 2004).
In gastric cancers like any other epithelial cancers, in order for tumours to become 
invasive and metastasise they must be able to break through the basement 
membrane, and invade through local connective tissue to metastasise to distant 
organs (Kleiner 1999). MMPs are important in this process.
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MMPs are regulated in several ways; the main specific inhibitors of MMP activity 
are the tissue inhibitors of matrix metalloproteinases (TIMPs).
Increased levels of TIMP-1, -2 and -4 have been found in gastric carcinoma biopsies 
(Koyama el al. 2004a, Kubben et al. 2006), and an association has been found 
between high TIMP levels and reduced survival in gastric cancer (Joo et al. 2000, 
Yoshikawa et al. 2001). Some TIMPs have roles in activating MMPs, for example a 
MMP-2/TIMP-2/MT1-MMP complex is formed on the cell surface, and releases 
MMP-2 when cleaved. This could be a factor in the increased TIMP expression seen 
in gastric cancer. Moreover, the TIMPs can affect cell growth and survival of the 
gastric cancer cells independently of their roles in MMP activation and inhibition 
(Koyama et al. 2004a). In a study by Bergin et al. (2004), there was no difference in 
TIMP-1 or -2 expression with H. pylori status; however infected individuals had 
higher MMP-9 activity. This imbalance in MMP and TIMP activity could have an 
important role in H. pylori induced gastritis, allowing MMP-induced degradation of 
the ECM.
Conversely, however, Western blot data from our laboratory show an increase in 
TIMP -1,-3 and -4 expression with H. pylori infection in the human gastric corpus. 
There was no change in the expression of TIMP-2 (fig 1).
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TIMP1 TIMP2 TIMP3 TIMP4
Fig 1: Expression of TIMP-1, 3 and 4 increased in H. p y lo r i infected human gastric 
corpus. Results from Western blot quantified by densitometry and normalised to 
GAPDH. (H .pylori negative n=13, H .pylori positive n=12). Data shown as fold 
increase ± SE *p<0.05 Student’s t-test. (Data supplied by A. Varro).
The aim of this part of the work was to investigate changes in TIMP expression in 
the gastric mucosa of human and a murine model. Quantitative real time PCR (Q- 
PCR) was used to investigate expression of TIMPs in transgenic mice that over 
express gastrin (Ins-GAS), and that are infected or not infected with Helicobacter 
felis, and also in gastric biopsy samples from patients with elevated gastrin 
associated with pernicious anaemia (PA).
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3.2 Materials and Methods
3.2.1 Samples
Samples of full thickness gastric corpus were taken from Ins-GAS mice. The Ins- 
GAS mice contain a transgene in which a rat insulin promoter drives a human gastrin 
minigene. Amidated gastrin is produced in p cells of the pancreas, and the mice have 
elevated gastrin levels. The mice were infected with H. felis and samples taken for 
RNA extraction at 3 and 6 months after infection, as previously described (McCaig 
et al. 2006).
Endoscopic pinch biopsies of gastric corpus were obtained from patients undergoing 
routine gastroscopy for investigation of dyspepsia. Samples were selected on the 
basis of plasma gastrin concentration. H. pylori status was assessed by serology, 
antral urease test and histology. Samples were placed in RNA later and stored prior 
to extraction of RNA.
Infusion of octreotide was administered to patients with large (>2cm) gastric ECL 
tumours over 72h (25pg/h). Plasma samples and gastric corpus biopsies were taken 
before and after treatment.
The study was approved by the Ethics committees of the South Sefton and the Royal 
Liverpool and Broadgreen University Hospitals NHS trusts. All patients gave 
informed written consent. The appropriate Home Office licenses were obtained in 
order to carry out animal work.
Mouse and human plasma samples were assayed for total amidated gastrin 
concentration as described previously (McCaig et al. 2006).
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3.2.2 Q-PCR Primer and probe optimisation
All mouse and human TIMP Q-PCR primers and probes were obtained from 
Eurogentec. All TIMP probes were 5’ FAM labelled and 3’ TAMRA labelled (for 
primer and probe sequences see Chapter 8.3). Mouse TIMP primers were made up to 
lOOpM stock in TE, and working solutions of lOpM made up in lOmM Tris. Mouse 
TIMP probes were made up to 20pM stock solutions in TE and working solutions of 
5pM were made up in lOmM Tris. Stock solutions were stored at -20°C and working 
solutions stored at 4°C. Human primer and probe sets were prepared to the same 
concentrations; however sterile distilled water rather than TE/Tris was used to make 
the dilutions.
Reaction concentrations of primers and probe for mouse TIMP-1 and -3 were 
optimised using cDNA derived from mouse kidney and TIMP-4 primers and probe 
were optimised using cDNA derived from mouse heart.
The human TIMP-1 and -3 primers used generate amplicons within a single exon 
and were therefore optimised using human genomic DNA (Promega). The human 
TIMP-2 and -4 primers both span and exon-exon junction were therefore optimised 
using cDNA derived from HeLa cells. For optimisation of primers, varying 
combinations of forward and reverse primer concentrations (50-900nM) were used 
(Table 1) and that giving the lowest Ct value adopted. Using the optimised primer 
concentrations the concentration of probe providing the lowest Ct value was then 
determined (Table 2).
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No of
replicates 4 
Primer
combination 50FS0R 50F/300R SOFSOOR 300F/50R 300FI300R 300F/9C0R 900FS0R 900F/300R 900F/900R
volume (pi)
Master mix 50 50 50 50 50 50 50 50 50
forward P 0.5 0.5 05 3 3 3 9 9 9
reverse P 0.5 3 9 05 3 9 0.5 3 9
probe 4 4 4 4 4 4 4 4 4
DNA 4 4 A 4 4 4 4 4 4
Water 41 385 325 385 36 30 325 30 24
total 100 100 100 100 100 100 100 100 100
Table 1: Primer optimisation template. The volumes shown provide master mixes to 
give 4 replicates. 9 different forward and reverse primer combinations are used 
varying between 50-900nM of each primer.
PROBE CONCENTRATION
25 50 75 100 125 150 175 200 225 
Num ber o f replicates 4 Total
Volum e (pi)
m astr mix 50 50 50 50 50 50 50 50 50 450
prim er F 3 3 3 3 3 3 3 3 3 27
prim er R 3 3 3 3 3 3 3 3 3 27
probe 0.5 1 1.5 2 2.5 3 3 5 4 4.5 22.5
□N A 4 4 4 4 4 4 4 4 4 36
w ater 39.5 39 38.5 38 37.5 37 36.5 36 35.5 337.5
total 100 100 100 100 100 100 100 100 100 900
Table 2: Probe optimisation template, shown for 4 replicates. Concentrations of 
probe are increased from 25-225nM in 9 reactions, previously determined optimal 
primer concentrations are used.
3.2.3 Q-PCR assays
In assays performed on mouse samples, gene expression in the test samples was 
compared to 18S RNA abundance as an endogenous control. The 18S kit (FAM-
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TAMRA labelled) was supplied by Eurogentec. Mouse samples were all diluted 1:10 
for measurement of 18S. In assays performed on human samples, gene expression 
was compared with both 18S RNA abundance and GAPDH abundance (GAPDH 
primers and probe; Yakima yellow-dark quencher, Eurogentec). Samples were 
diluted 1:100 for 18S measurement.
A 2x master mix (Eurogentec) containing Uracil-N-glycosylase (UNG), to prevent 
carry over contamination was used for most Q-PCR reactions. For the assays on 
human samples with TIMP-2 and -4 a mastermix without UNG was used, which 
provides greater sensitivity.
For measuring 18S RNA abundance each reaction contained; 50pl 2x master mix 
(Eurogentec), 6pl primer mix (600nM), 2pl probe (125nM), 4pl DNA and 3 8pi 
water. This gave a total volume of lOOpl and three 25pi replicates were used in the 
assay.
For each sample measured with GAPDH the reaction contained 50pl 2x master mix 
(Eurogentec), 2pl of each primer (200nM), 2pl of each, probe (lOOnM), 4pl DNA 
and 40pl water to make up to lOOpl.
Mouse genomic DNA (Promega) was used to construct a standard curve for 18S in 
the reactions using mouse samples. Four serial dilutions of neat, 1:10, 1:100 and 
1:1000 were used to construct this standard curve (concentration of neat genomic 
DNA lOOng/pl). Human genomic DNA (Promega) was used to construct 18S and 
GAPDH standard curves in assays using human sample. The dilutions used were 
neat, 1:10, 1:100, 1:1000 and 1:10000 (concentration of neat genomic DNA 
lOOng/pl).
For experiments using FAM-TAMRA labelled primers and probes, (mouse and 
human TIMP and 18S), detection was performed using the FAM dye layer with
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TAMRA as the quencher. The GAPDH primers and probes were Yakima yellow- 
dark quencher labelled and detection was performed using the VIC dye layer, with 
no quencher.
In assays measuring TIMP expression in mouse samples mouse heart cDNA was 
used to construct the standard curves. Dilutions of 1:50, 1:100, 1:250 and 1: 1000 
were used for TIMP-3 and dilutions of 1:5, 1:10, 1:25 and 1:100 for TIMP-2 and -4 
(concentration of undiluted heart cDNA 1.83pg/pl). In assays measuring TIMP 
expression in human samples, human genomic DNA (Promega) was diluted 1:100, 
1:1000, 1:10 000, 1:100 000 for TIMP-3 and 1:100, 1:400, 1:2000, 1:10 000 and 
1:50 000 for TIMP-1. For assays to measure human TIMP-2 and -4, HeLa cell 
cDNA was used neat and diluted 1:10, 1:100 and 1:1000 (concentration of undiluted 
HeLa cDNA 1.9pg/pl).
3.3 Results
3.3.1 Optimisation of TIMP primers and probes for q-PCR
Mouse TIMP primer and probe optimisation determined that the quantities shown in 
table 3 gave the lowest Ct values. These values were used for all reactions to 
measure TIMP expression in mouse samples, to give optimal results.
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mTIMPI mTIMP3 mTIMP4
Volume (pi)
Master Mix 50 50 50
Primer F 3 9 9
Primer R 9 3 3
Probe 4.5 3.5 4
DNA 4 4 4
SDW 29.5 30.5 30
total 100 100 100
Table 3: Volumes (pi) of reagents, determined by optimisation experiments, added 
per sample for Q-PCR assays on mouse cDNA samples. Working concentration of 
primers lOpM and probes 5pM.
Human TIMP primer and probe optimisation determined that the quantities shown in 
table 4 gave the lowest Ct values. These values were used for all reactions to 
measure human TIMP expression to give optimal results.
These values give a total of lOOpl, this is used to give three 25pi replicates for the Q- 
PCR assay.
70
Chapter 3 -  Expression and regulation o f TIMPs in human and murine stomach by H e lic o b a c te r  and gastrin.
hTIMPI hTIMP2 hTIMP3 hTIMP4
Volume (pi)
Master Mix 50 50 50 50
Primer F 3 3 3 3
Primer R 9 3 3 3
Probe 4 4 4.5 4
DNA 4 4 4 4
SDW 30 36 35.5 36
total 100 100 100 100
Table 4: Volumes (pi) of reagents, determined by optimisation experiments, added 
per sample for Q-PCR assays on human cDNA samples. Working concentration of 
primers lOpM and probes 5pM.
The optimisation assays for each primer set and probe allowed determination of 
which combination of primer concentrations and which probe concentration gave the 
lowest Ct value. This indicated the highest assay sensitivity. These concentrations 
were used in all subsequent assays in order to achieve optimal results. An example of 
a result from a primer and probe concentration optimisation experiment is shown in 
Fig 2. The optimal combinations for each primer set and probe are shown in table 5.
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A
Fig 2: One example of primer and probe optimisation result (mouse TIMP-4). A. 
The primer combination giving the lowest Ct value is chosen, in this case 900nM 
forward primer and 300nM reverse primer. B. The probe concentration giving the 
lowest Ct value is chosen, in this case 200nM.
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TIMP Primer Concentrations (nM) Probe Concentration (nM)
Mouse TIMP 1 300F/900R 225
Mouse TIMP 3 900F/300R 175
Mouse TIMP 4 900F/300R 200
Human TIMP 1 300F/900R 200
Human TIMP 2 300F/300R 200
Human TIMP 3 300F/900R 225
Human TIMP 4 300F/300R 200
Table 5: The concentrations of forward and reverse primers, and probes, used for 
TIMP Q-PCR assays.
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3.3.3 TEMP expression is increased in Ins-GAS mice 6 months after H. felis 
infection
Q-PCR was carried out to investigate TIMP expression in the gastric corpus of Ins- 
GAS mice. There was an increase in TIMP-1 and -3 expression compared to 
uninfected control Ins-GAS mice after six months infection with H. felis. Three 
months after infection there was no difference in TIMP expression between the two 
groups (Fig 3). The expression of TIMP-4 was below the level of detection using this 
method.
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Fig 3: Q-PCR on gastric corpus samples from Ins-GAS mice infected or non-infected with H. fe lis. A. 
Three months after H. fe lis  infection there was no change in TIMP-1 or -3 expression in Ins-GAS 
mice, B. 6 months after H. fe l is  infection expression o f  TIMP-1 and -3 increased in infected mice 
compared to the non-infected controls. TIMP values normalised to 18S and expressed as percent o f  
uninfected controls ± SE. C. At 3and 6 months there was no significant difference in plasma gastrin 
levels. Control, n = 5; H felis , n = 5. *p<0.05 Student’s t-test.
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3.3.4 TIMP expression is increased in patients with pathologically elevated 
gastrin due to PA.
Since gastrin is known to affect gastric epithelial architecture Q-PCR was carried out 
on human corpus biopsies from patients with pathologically high gastrin due to PA. 
The results showed that expression of all TIMPs increased significantly in this 
patient group, compared to patients with normal gastrin concentrations (<40pM) (Fig
4).
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Fig 4: TIMP expression was increased in patients with elevated circulating gastrin due to 
PA. A. Expression o f  TIMPs 1-4 was increased in PA patients compared to patients with 
normal gastrin levels. C. Typical circulating gastrin concentration (pM) in PA patients 
compared to control unaffected patients. TIMP values normalised to GAPDH and expressed 
as percent o f  controls ± SE. Control, n = 8-15; PA, n = 13-16. *p<0.05 Student’s t-test.
75
Chapter 3 -  Expression and regulation o f  TIMPs in human and murine stomach by H e lic o b a c te r  and gastrin.
3.3.5 Hypergastrinaemia induced TIMP overexpression in PA is reduced 
following antrectomy and somatostatin analogue treatment
In patients with very high gastrin levels associated with PA, TIMP expression in 
gastric corpus was increased (Fig 4). When two such patients were treated with 
octreotide, a somatostatin analogue, for 72h both patients showed a reduction in 
TIMP expression. Moreover after undergoing an antrectomy to permanently reduce 
the gastrin drive TIMP expression was reduced by almost 50% in two further 
patients (Fig 5).
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Fig 5: Reduced TIMP expression after octreotide infusion and antrectomy. (A) and (B) In 2 
patients with TIMP overexpression due to PA, expression o f TIMP-1 and -3 was reduced 
following antrectomy. (C) and (D) Following octreotide treatment TIMP expression also 
reduced in two other PA patients. In all cases TIMP expression was normalised to GAPDH 
in the same sample. Gastrin concentrations (pM): patient 1 pre 2800, post 112; patient 2 pre 
1080, post 24; patient 3 pre 680, post 215; patient 4 pre 3400, post 490. (n=l).
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3.4 Discussion
Before starting to perform Q-PCR reactions all the TIMP primer and probe sets 
intended for use required optimisation, to ensure maximum assay sensitivity was 
achieved. This entailed finding a suitable cDNA to use in the optimisation assays, 
and where necessary, for standard curves. In order to optimise the mouse TIMP 
primer sets mouse heart, liver and kidney cDNA were initially used. These tissues 
were chosen because all were easy to obtain and also expressed TIMPs to an 
adequate level. The best results were obtained using kidney cDNA for mouse TIMP- 
1 and -3 and mouse heart cDNA for TIMP-4. The appropriate tissue was chosen by 
running real time PCR assays with the TIMP primers and probes to discover which 
cDNA gave the best amplification (lowest Ct value). Mouse heart cDNA was 
subsequently used to generate a standard curve in assays to measure all three TIMPs, 
although kidney cDNA was used to optimise the TIMP-1 and 3 primers and probes. 
The reason for this was that there was not a great deal of difference between the 
results obtained with kidney or heart cDNA and by using heart the standard curves 
generated in all assays on the mouse samples used the same cDNA, from a single 
reverse transcription.
The human TIMP-1 and -3 primers and probes could be optimised using human 
genomic DNA because these primers did not span an exon-exon boundary. However 
the primers for human TIMP-2 and -4 did span an exon-exon boundary and therefore 
another source of DNA needed to be used for these optimisations. A suitable source 
of cDNA was found in a similar way as for the mouse assays. cDNA was prepared 
from human cell lines, HeLa, CaCo2 (a human colon cancer cell line), and AGS-Gr
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cells (a human gastric cancer cell line). Q-PCR assays were carried out with the 
TIMP primers and probes to discover which cDNA gave the best amplification 
(lowest Ct value). The best results were seen with HeLa cell cDNA and this was 
subsequently used for optimisation and also for standard curves in assays measuring 
human TIMP-2 and -4 expression.
Expression of all mouse TIMPs was compared to expression of 18S RNA in the 
same sample, to give a ratio for TIMP expression. Initially 18S expression was also 
determined for each human sample but it was found, however that for the human 
samples, standardization against GAPDH provided more consistent data.
Expression of TIMP-1 and -3 was increased in Ins-GAS mice, six months after 
infection with H. felis, compared to the non-infected control mice. There was no 
difference in TIMP expression three months after infection; in fact TIMP expression 
was very low in all samples prior to 6 months. TIMP-4 expression was investigated 
in the same samples, however the expression was too low to detect by q-PCR. A 
reason for this may be a variation in the sensitivity of the primers and probe. TIMP-2 
expression was not investigated in the Ins-GAS mice because the preliminary data 
using human samples had shown no difference in TIMP-2 expression with H. pylori 
infection.
These results from the mouse samples are interesting as they are similar to those seen 
when investigating TIMP expression with H. pylori infection in humans. In both 
humans and mice Helicobacter infection induces overexpression of TIMP-1 and -3. 
It is useful to have an animal model for investigation of TIMP expression in 
response to Helicobacter infection, using an animal model will enable more control
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over experimental factors such as age, weight, environment and time of infection and 
thus reduce variability.
Ins-GAS mice have raised plasma gastrin concentrations. They show increased 
proliferation in the gastric mucosa and, after 4 months of age, loss of parietal cells 
with subsequent decrease in acid secretion. The mice develop hyperplasia, similar to 
that seen in humans with CAG. Older mice have an increased tendency to develop 
gastric cancer; this is accelerated with Helicobacter infection (Wang el al. 1996, 
Wang et al. 2000). Gastrin levels in the Ins-GAS mouse samples used were similar 
in the control and infected mice. This suggests that in these experiments 
inflammation due to H. felis infection rather than hypergastrinaemia was responsible 
for the increase in TIMP expression.
TIMP expression may increase during Helicobacter infection, to compensate for the 
increase in the expression of MMPs, for example, MMP-7 expression was increased 
in gastric epithelial cells following H. pylori infection (Wroblewski et al. 2003). 
Presumably, MMP expression increases with infection due to host response to 
inflammation and remodelling of the ECM. Alternatively TIMP expression could 
increase for reasons independent of MMP inhibition.
The results show that expression of all four TIMPs increased significantly in gastric 
biopsy samples from patients with PA, compared to samples from patients with 
normal gastrin levels (<30pM). In PA, circulating gastrin levels become extremely 
high, and the condition develops over many years, these patients could have 
circulating gastrin concentrations of 2000pM, over 10 times higher than normal, 
persisting over a period of several years. There was no significant increase in TIMP 
expression between patients with normal gastrin levels and those with elevated
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gastrin due to conditions other than PA, such as gastrinoma or treatment with proton 
pump inhibitors (PPIs) (data not shown). PPIs are not likely to result in such high 
gastrin levels as those seen in PA, and this would occur over a shorter period of time. 
Gastrinoma may result in very high gastrin levels, although as with PPIs this would 
be present over a shorter time period. This suggests that very high gastrin levels, or 
that elevated gastrin over a very long period of time is required to increase TIMP 
expression.
Another interesting point arising from the data is that although Helicobacter 
infection did not increase TIMP-2 expression in humans (Fig. 2 and Bodger el al. 
2008), elevated gastrin in PA did increase its expression. H. pylori infection is 
associated with gastric cancer (Uemura et al. 2001), and it is possible that 
hypergastrinaemia could exacerbate the effects of inflammation due to this infection, 
which is known to cause an increase in gastrin concentration, although not to such 
high levels as seen in PA (Calam et al. 1997). All the patient samples used in this 
work were H. pylori negative.
In the normal condition, acid from the parietal cells stimulates release of 
somatostatin from D-cells in the antrum, which inhibits gastrin release from G-cells. 
In PA there is loss of parietal cells therefore no somatostatin is released, this leads to 
hypergastrinaemia and commonly ECL cell hyperplasia (Jensen 2002) (fig 6). Also 
elevated gastrin leads to the induction of ECL cell gene expression, such as histidine 
decarboxylase (HDC), chromogranin A (CGA), vesicular monoamine transporter 
type 2 (VMAT2) (Dimaline et al. 1993a , Dimaline et al. 1993b, Dimaline and 
Struthers 1996), and also Reg la, which may function as a tumour suppressor 
(Higham et al. 1999).
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Fig 6: A schematic representation o f the development o f  hypergastrinaemia in PA. In the 
normal stomach G-cells release gastrin in response to food intake. Gastrin causes ECL cells 
to release histamine which stimulates acid secretion from parietal cells, this feeds back on D- 
cells which release somatostatin to inhibit further gastrin release (see Chi Fig 2). In PA there 
is loss o f parietal cells, and therefore acid release. There is no somatostatin feedback and 
therefore gastrin production becomes elevated leading to ECL cell hyperplasia and in some 
cases the development o f  ECL carcinoid tumours.
In 5-10% of patients with PA, ECL hyperplasia progresses to the development of 
gastric carcinoid tumours (Bordi et al. 1991, Bordi et al. 1995), the majority of these 
tumours are small (<lcm) and are rarely metastatic (Solcia et al. 1991, Modlin et al. 
1995), however larger carcinoid tumours (>2cm) carry a significant risk of leading to 
metastasis (Thomas et al. 1995). Antrectomy has been performed to treat small ECL 
tumours, by removing the gastrin secreting G-cells located in the antrum. However 
when larger tumours are present total gastrectomy has been advised due to the risk of 
metastasis (Hirschowitz et al. 1992, Thomas et al. 1994).
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Octreotide is a somatostatin analogue and is known to decrease plasma gastrin levels 
and reduce ECL cell number in patients with chronic atrophic gastritis (Bordi et al. 
1993, Ferraro et al. 1996). An octreotide suppression test, as described by Higham et 
al. (1998), was used to determine whether large carcinoid tumours were responsive 
to gastrin, and thus whether antrectomy would be an appropriate treatment. Infusion 
of octreotide over 72h resulted in the temporary reduction of plasma gastrin levels, 
and depression in ECL cell function (assessed by gene expression), indicating that 
these cells were responsive to gastrin and that antrectomy would be therapeutically 
beneficial. Indeed antrectomy, performed 3 months following the suppression test, 
resulted in the regression of the ECL carcinoid tumours. The octreotide suppression 
test is therefore a useful tool to determine whether antrectomy, rather than total 
gastrectomy, is an appropriate treatment for large ECL carcinoid tumours.
Samples were obtained from patients with hypergastrinaemia due to PA after 72h 
octreotide infusion, and also pre and 1-3 years post antrectomy. These data showed 
that antrectomy caused a reduction in TIMP expression in both patients tested. In 
two other PA patients TIMP overexpression was reduced after octreotide supression 
tests. The results suggest that upregulation of TIMP expression due to PA is reversed 
after long term reduction of gastrin secretion by antrectomy.
In conclusion the results shown in this chapter indicate that TIMP expression in the 
gastric epithelium increases with Helicobacter infection in Ins-GAS mice and 
humans. Also TIMP expression increases in the corpus of the stomach in patients 
with elevated gastrin due to PA. This upregulation is reduced by performing an 
antrectomy which lowers circulating gastrin levels.
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4.1 Introduction
Interactions between epithelial cells and mesenchymal cells are very important in 
maintaining normal mucosal organisation. This occurs during normal physiological 
processes such as development and wound healing, but also in pathology such as 
progression to cancer.
Epithelial and sub-epithelial cells may release growth factors, cytokines and 
extracellular proteases, such as MMPs, and protease inhibitors, as a way to 
communicate with each other, and alter the microenvironment.
Examples of dysfunction in this system are H. pylori infection which causes 
inflammation of the gastric mucosa, and in some patients leads to gastric cancer 
(Correa & Chen 1994), and also prolonged hypergastrinaemia in patients with 
pernicious anaemia (PA) leading to ECL cell carcinoid tumours (Bordi et al. 1995).
Myofibroblasts are an important sub-epithelial cell type due to their ability to 
produce epithelial growth factors and their close proximity to the epithelial cells.
Previous work carried out in this laboratory has shown that H. pylori infection 
increases the production of MMP-7 by gastric epithelial cells (Wroblewski et al. 
2003). MMP-7 acts as a myofibroblast growth factor by promoting the cleavage of 
IGFBP-5, secreted by myofibroblasts, to liberate IGF-II, which stimulates gastric 
epithelial cell proliferation and myofibroblast proliferation and migration. Over time 
increased numbers of myofibroblasts can lead to hyperproliferation and increase the
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chance of developing malignant transformations (Hemers et al. 2005, McCaig et al. 
2006).
Immunohistochemistry (IHC) performed on endoscopic biopsy samples from H. 
pylori positive gastric corpus mucosa to determine cellular localisation of TIMPs in 
the gastric mucosa showed differences in the localisation of TIMP-1, -3 and -4. 
TIMP-1 was localised in epithelial and inflammatory cells, and also in 
myofibroblasts. TIMP-3 showed strong expression in myofibroblasts, and was also 
present in epithelial and inflammatory cells. TIMP-4 was localised mostly to 
epithelial and inflammatory cells, and was not present in myofibroblasts (Fig 1 A-F). 
TIMPs were very weakly stained in H. pylori negative samples (data not shown). 
(Bodger et al. 2008).
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TIMP-1 TIMP-3 TIMP-4
Fig 1: Immunohistochemical staining showing localisation of TIMP proteins in 
formalin fixed sections from H. p y lo r i positive gastric corpus mucosa. A. x200 
magnification image showing TIMP-1 staining in glandular epithelial cells (g) and 
inflammatory cells (i). B. x400 magnification image showing weak positivity for 
TIMP-1 in myofibroblasts (m). C. x200 magnification showing TIMP-3 positivity in 
surface (s) and glandular epithelial cells. D. x200 magnification showing TIMP-3 
positivity in myofibroblasts and inflammatory cells. E.x200 magnification image 
showing TIMP-4 staining in surface and glandular epithelial cells. F. x200 
magnification image showing TIMP-4 positivity in glandular epithelial cells. IHC 
from Bodger et al. 2008.
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The role of MMPs in epithelial-mesenchymal signalling, and in the development of 
gastric cancer, makes investigating the role of their natural inhibitors, the TIMPs, in 
these processes relevant and important.
This chapter focuses on the expression and biological relevance of TIMPs both in 
gastric epithelial and sub-epithelial cells, in particular in gastric myofibroblasts and 
in a gastric cancer cell line, AGS-Gr.
4.2 Materials and Methods
4.2.1 Stimulation of cultured cells for protein extraction
4.2.1.1 Myofibroblasts
Cells were grown until 80-90% confluent in full serum medium (FSM) in T75 
culture flasks, and then serum starved for 20-24h prior to stimulation. Cells were 
stimulated for 24h by adding HGF (hepatocyte growth factor) (40ng/ml), TGF-P 
(transforming growth factor-beta) (2.5ng/ml) or PDGF (platelet-derived growth 
factor) AA and BB isoforms (lOng/ml each) to the cells in 10ml serum free medium 
(SFM).
4.2.1.2 AGS-Gr
Cells were grown in 10cm2 culture dishes for 48h in 10ml FSM. Cells were 
stimulated with 5nM G17 (Bachem) in 10ml SFM for 24h. Control (unstimulated)
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cells were incubated in 10ml SFM for 24h prior to protein extraction (see chapter
2.2.2).
4.2.2 Western Blotting
80pg myofibroblast or 60pg AGS-Gr cell lysates, and 20pl each media sample from 
equal cell numbers, were loaded per well of a 12% SDS-polyacrylamide gel. See 
chapter 8.4 for antibody details and dilutions.
4.2.3 Immunocytochemistry
Myofibroblasts were seeded into 4-well chamber slides, 20,000 cells per well, and 
left in FSM for 24h. Cells were then serum starved for 24h before fixing in 4% 
paraformaldehyde and incubating with TIMP primary antibodies.
AGS-Gr cells were seeded in 4-well chamber slides at 50,000 cells per well and left 
in FSM for 24h. Cells were stimulated with 5nM G17 (Bachem) in 1ml SFM per 
well for 24h. Control (unstimulated) cells were incubated in 1ml SFM/well for 24h 
prior to fixing.
AGS-Gr cells transfected with TIMP-3 siRNA (Ambion, Warrington UK, details of 
transfection procedure in chapter 2.2.9.1) were seeded in 4-well chamber slides, 
approximately 20,000 cells per well, and left in FSM for 72h following transfection. 
Cells were then stimulated with 5nM G17 (Bachem) in 1ml SFM/well for 16h prior 
to fixing. See chapter 8.5 details and dilutions.
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4.2.4 Transfection of AGS-Gr cells with siRNA
AGS-Gr cells were transfected with TIMP-3 siRNA (50pM), or scrambled control 
RNA (62 pM) by nucleofection, using amaxa cell line nucleofector solution. Full 
details of transfection procedure in chapter 2.2.9.1
4.2.5 Boyden Chamber migration Assays
Non-transfected AGS-Gr cells were grown until confluent in T75 tissue culture 
flasks. AGS-Gr cells transfected with TIMP-3 siRNA (Ambion) were grown in T25 
tissue culture flasks for 72h following transfection.
Migration assays were performed in 24-well 8pm pore Boyden chambers (Becton 
Dickinson, Oxford, UK). The Boyden chamber approach involves two chambers 
(Fig 2) separated by a filter through which cells migrate. Chemotactic gradients can 
be set up by placing the chemo-attractant in the lower chamber and the cells in the 
upper chamber. The cells in question migrate through the pores in the filter to enter 
the lower chamber. The number of cells on the lower side of the filter are then fixed, 
stained and counted.
Upper Chamber 
Filter
Lower Chamber
Fig 2: The Boyden Chamber. Cells are placed in the upper chamber and chemo­
attractant in the lower chamber. The cells migrate through pores in the filter.
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Confluent cells were detached using 0.02% EDTA and then diluted in SFM before 
counting.
25,000 cells were added to 0.5ml SFM/well and this was added to the wells. 0.75ml 
SFM was added to the lower chambers, with 5nM G17 added to the required wells. 
The plates were incubated at 37°C for 16h and cells migrating through the membrane 
were counted on the lower surface using Diff-Quick differential staining kit (Dade 
Behring Inc, Newark DE). Total cells in 5 fields were counted per triplicate, and the 
mean taken.
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4.3 Results
4.3.1 TEMP-1, -2, -3 and -4 are expressed in myofibroblasts of patients with 
gastric adenocarcinoma
Since IHC showed expression of TIMP-1 and -3 in gastric myofibroblasts, Western 
blotting was performed on whole cell lysates from cultured gastric myofibroblasts. 
This showed that all four TIMPs were expressed in patients with gastric 
adenocarcinoma (Fig 3). TIMP-1, -2 and -4 expression was increased in 
myofibroblasts derived from the tumour, compared to adjacent normal tissue. TIMP- 
3 was expressed to a similar level in both sets of cells.
4.3.2 TEMP -1 and - 3 are expressed in gastric myofibroblasts
The finding that TIMP-1 and -3 were expressed in sub-epithelial cells shown by 
IHC, and Western blotting is consistent with the expression of TIMPs 1-4 in cultured 
myofibroblasts from a patient with gastric adenocarcinoma. TIMP-3 expression was 
also strong in myofibroblasts from adjacent normal tissue; therefore 
immunocytochemistry was carried out to investigate the localisation of TIMP-1 and - 
3 in these cultured gastric myofibroblasts (Fig 4). This shows that TIMP-1 and -3 are 
both expressed with a cytoplasmic localisation in myofibroblasts from the site of a 
gastric adenocarcinoma, and in myofibroblasts from adjacent normal tissue.
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Fig 3: Western blots showing TIMP expression in myofibroblasts from a gastric 
adenocarcinoma. A. Lysates from cells taken from the tumour. B. Cell lysates from adjacent 
normal tissue. GAPDH is shown as a loading control (Representative gels from 2-3 
experiments).
Fig 4: Immunocytochemistry showing cytoplasmic localisation o f TIMP-1 and -3 in gastric 
myofibroblasts. A cancer derived myofibroblasts, B are myofibroblasts derived from 
adjacent normal tissue (Representative images from 2-3 experiments). Scale bars represent 
20pm. Deconvolution was performed using AxioVision 4.6 imaging software (Zeiss, 
Welwyn Garden City, UK).
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4.3.3 HGF and TGF-P stimulates expression of TIMP-1 in gastric 
myofibroblasts
To study the regulation of TIMPs in gastric myofibroblasts by growth factors 
Western blotting was performed. This showed that gastric myofibroblasts derived 
from normal gastric corpus mucosa, stimulated with HGF and TGF-P, had increased 
abundance of TIMP-1 in the medium compared to control cells (Fig 5B). PDGF did 
not alter TIMP-1 levels in the medium compared to the control. These data were 
normalised to the amount of total protein present in the medium (Fig 5 A). TIMP-1 
expression was below the limit of detection by Western Blotting in cell lysates from 
these myofibroblasts.
A B
Fig 5: A. Abundance of TIMP-1 in medium from human gastric myofibroblasts 
from a normal patient is stimulated by HGF and TGF-P, compared to control 
unstimulated, cells. Relative protein abundance was measured by densitometry and 
normalised to the total amount of protein present in the sample (n=l). B. 
Representative Western Blot image showing expression of TIMP-1 in medium from 
gastric myofibroblasts stimulated with HGF, PDGF and TGF-p. Total amount of 
protein in media samples (mg/ml); control 0.78, HGF 0.74, PDGF 0.82, TGF-P 0.72.
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4.3.4 HGF, PDGF and TGF-P stimulated expression of TIMP-3 in gastric 
myofibroblasts
Western blotting showed that stimulation of gastric myofibroblasts derived from 
normal human gastric corpus mucosa with HGF, PDGF and TGF-P increased 
expression of TIMP-3 in whole cell lysates compared to control cells (Fig 6 A and 
B). TIMP-3 abundance was below the limit of detection in the medium from these 
cells by Western Blotting.
A B
| S  C HGF PDGF TGF-p
Fig 6: A. TIMP-3 expression in cell extracts from normal human gastric 
myofibroblasts was stimulated by HGF, PDGF and TGF-P, compared to control 
unstimulated cells. Data quantified by densitometry and normalised to GAPDH 
(n=l). B. Representative Western blot image showing expression of TIMP-3 in 
gastric myofibroblasts stimulated by HGF, and PDGF and TGF-p. GAPDH is shown 
as a loading control.
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4.3.5 TIMP-1, - 3 and -4 are expressed in AGS-Gr cells but only TIMP-3 
expression is induced by gastrin
TIMPs were shown by Western Blot to be expressed in myofibroblasts from the site 
of gastric adenocarcinoma, and Immunocytochemistry showed TIMP-1 and -3 
expression in myofibroblasts from adjacent normal tissue. TIMP-1 and -3 expression 
was also shown to be regulated by growth factors in myofibroblasts. I then wanted to 
investigate the expression and regulation of TIMPs in a gastric cancer cell line, 
AGS-Gr.
Immunocytochemistry was performed to investigate the expression of TIMP-1, -3 
and -4 in AGS-Gr cells (Fig 7A). TIMP-1, -3 and -4 were all expressed in this cell 
type, showing a cytoplasmic localisation. Under control, non-stimulated conditions 
expression of TIMP-3 was much lower than the expression of TIMP-1 and -4. 
Stimulation with 5nM G17 resulted in an increase in TIMP-3 expression. G17 
stimulation did not appear to alter the expression of TIMP-1 or -4. A Western Blot 
was carried out to confirm the affect of G17 on the expression of TIMP-3 in AGS- 
Gr cells (Fig 7B). This showed a substantial increase in TIMP-3 expression after 
stimulation of the cells with 5nM G17 for 24h, compared to the non-stimulated cells.
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Fig 7: A. Immunocytochemistry showing staining of TIMP-1, -3 and -4 in AGS-GR 
cells (indicated by arrows). The top images show TIMP-1, -3 and -4 staining in 
cells not stimulated with gastrin. The bottom images show cells stimulated for 8h 
with InM gastrin. The expression of TIMP-1 and -4 shows no change with gastrin 
stimulation but TIMP-3 expression was very low in non-stimulated cells and 
increased following 8h stimulation with InM G17 (n=3) . Scale bars represent 
20pm. B. Western Blot showing upregulation of TIMP-3 expression with 24h 5nM 
G17 stimulation (n=2). GAPDH is shown as a loading control. C. Percentage of 
cells expressing TIMP-3 (measured by Immunocytochemistry). Values are 
percentage ± SE.
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4.3.6 Gastrin induces c-fos expression in AGS-Gr cells
It is clear that TIMP-3 expression in AGS-Gr cells is stimulated by G17. Previous 
reports have linked gastrin stimulation to the activation of the immediate early 
response gene c-fos, which then induces the expression of other genes. 
Immunocytochemistry was performed to establish whether G17 stimulation of AGS- 
Gr cells induced expression of c-fos. The data show that stimulation with 5nM G17 
for 2h did indeed stimulate c-fos expression in the nuclei of AGS-Gr cells. In 
control, unstimulated cells, no c-fos expression was seen (fig 8).
Gastrin “ +
c-fos
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Fig 8: Immunohistochemistry showing c-fos expression in AGS-Gr cells (indicated 
by arrows). A and B show no c-fos staining in unstimulated cells, C and D show c- 
fos staining after stimulation with 5nM G17 for 2h. Scale bars represent 20pm. E. 
Percentage of c-fos expressing cells ± SE. n=2.
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4.3.7 TEVLP-3 inhibits migration of AGS-Gr cells
The above findings indicate that TIMP-3 is upregulated in AGS-Gr cells in response 
to G17 stimulation. To study the functional significance of this upregulation I went 
on to investigate the effect of TIMP-3 upregulation on the function of AGS-Gr cells. 
As I mentioned in the introduction G17 stimulates the migration of AGS-Gr cells. 
Incubation of AGS-Gr cells with recombinant TIMP-3 inhibited gastrin-induced 
migration of the cells in Boyden chamber (Fig 9A).
Knocking down TIMP-3 expression with siRNA resulted in an increase in migration 
of gastrin stimulated AGS-Gr cells in Boyden chamber (Fig 9B). 
Immunocytochemistry verified a 54.7% knock-down of TIMP-3 expression in cells 
transfected with siRNA (fig 9 C & D).
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Fig 9: A. Addition o f AGS-GR cells with recombinant TIMP-3 inhibits gastrin mediated 
stimulation o f migration through Boyden chambers. B. Knock down of TIMP-3 expression 
in AGS-Gr cells with siRNA stimulates migration through Boyden chambers. Cells were 
stimulated with 5nM G17 for 16h, results show number o f migrating cells ± SE. *p< 0.05 
Student’s t-test, n=3. C. Immunocytochemistry showing knockdown of TIMP-3 in AGS-GR 
after transfection with TIMP-3 siRNA. Scale bars represent 20pm. TIMP-3 indicated by 
arrows. n=3. D. Percentage knockdown o f TIMP-3 after siRNA treatment. n=3.
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4.4 Discussion
Immunohistochemistry confirmed that TIMPs are expressed in a variety of cell types 
in H. pylori positive gastric mucosa. TIMP-1, -3 and -4 showed differences in their 
individual cellular localisations. TIMP-1, -3 and -4 were expressed strongly in 
glandular epithelial cells. TIMP-3 and -4 were expressed in inflammatory cells, but 
TIMP-1 showed only weak positivity in these cells. TIMP-3 showed strong staining 
in myofibroblasts, while TIMP-1 showed weaker expression in myofibroblasts. 
TIMP-4 was localised exclusively in epithelial cells and not seen in myofibroblasts. 
This difference in cellular localisation between the individual TIMPs is interesting as 
it suggests varying roles for each TIMP in the gastric mucosa, and also suggests that 
the expression of each TIMP in the gastric mucosa is influenced in a different way 
by H. pylori infection.
Infection with H. pylori is known to increase the expression of MMPs, and that this 
is significant in the remodelling process that occurs with infection, and that may lead 
to gastric cancer (Wroblewski et al. 2003, Hemers et al. 2005, McCaig et al. 2006). 
Increased TIMP expression with H. pylori infection may be related to increased 
MMP expression. TIMPs also have roles that are independent of MMP inhibition 
(Lambert et al. 2004), which could also have important consequences in TIMP 
upregulation with H. pylori infection.
Myofibroblasts from a patient with gastric adenocarcinoma have been prepared and 
cultured in the laboratory. There are cell cultures from the site of the tumour, and 
from adjacent macroscopically normal tissue. Western immunoblotting on lysates
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from these cells showed expression of TIMP-1, -2, -3 and -4 in cells from the 
tumour, and TIMP-1, -2 and -4 expression was increased in the tumour derived 
compared to adjacent normal tissue derived myofibroblasts.
Immunocytochemistry showed staining for TIMP-1 and -3 in the same cultured 
myofibroblasts, in cells from the tumour and those from adjacent normal tissue. This 
shows that cultured myofibroblasts do express TIMPs and therefore can be used to 
investigate TIMP expression and function.
Stimulation of myofibroblasts with HGF and TGF-P caused an increase in TIMP-1 
abundance in the culture medium from these cells. Stimulation with HGF, PDGF and 
TGF-P stimulated TIMP-3 expression in whole cell lysates from myofibroblasts, 
showing that TIMP expression in myofibroblasts can be stimulated by growth 
factors.
TGF-p inhibits proliferation and therefore acts as a tumour suppressor in the early 
stages of cancer. However as cancer progresses cancer cells can develop resistance 
to TGF-P and also cancer cells can release non-physiological levels of TGF-P which 
may affect tumour cell differentiation thus leading to metastasis (Moustakas et al. 
2002). Increased levels of TIMPs in myofibroblasts in response to TGF-P could be 
due to their roles in inhibition of ECM breakdown, or inhibition of proliferation. 
TIMPs have also been found to promote metastasis in some tissues (Baker et al. 
2002).
TIMPs could also be influenced by TGF-p because of its involvement in fibrosis. An 
abnormally high level of TGF-p is a major factor in the development of kidney 
fibrosis (Moustakas & Heldin 2007).
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TGF-P signalling in stromal myofibroblasts induces expression of HGF, and this 
promotes enhanced proliferation and invasion (Moustakas & Heldin 2007).
PDGF is a mitogen for many types of cell of mesenchymal origin and has roles in 
promoting cell migration and survival (Tallquist et al. 2004). TIMPs have roles in 
inhibiting cell migration (Anand-Apte et al. 1996, Oh et al. 2004) and inhibiting 
apoptosis (Jiang et al. 2002), which could explain the increase in their expression.
TEMP expression has been stimulated in other cell types by growth factors, for 
example TGF-P induced TIMP-1 expression in cultured intestinal myofibroblasts 
and myometrial smooth muscle cells, and induced TIMP-3 expression in lung 
fibroblasts and human chondrocytes. However TGF-P had no effect on TIMP-2 
expression in myometrial smooth muscle cells (Ma et al. 1999, McKaig et al. 2003, 
Qureshi et al. 2005, Garcia-Alvarez et al. 2006). PDGF induced TIMP-1 expression 
in human dermal fibroblasts, but had no effect on TIMP-2 expression in the same 
cells (Jinnin et al. 2005).
It is interesting that the expression of the different TIMPs varies in the gastric 
myofibroblasts. This suggests the different TIMPs have different roles and are 
regulated differently in this cell type. TIMP-1 was upregulated by growth factors in 
media from stimulated myofibroblasts while TIMP-3 was upregulated by growth 
factors in the cell lysates and not in medium. This could be due to TIMP-1 and -3 
having different roles in the gastric myofibroblasts. TIMP-3, unlike the other TIMPs, 
is tightly bound to the extracellular matrix and thus is not secreted like the other 
TIMPs, and would not be seen in culture medium (Woessner 2001).
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From this part of the work it is clear that TIMP-1 and -3 are expressed in gastric 
myofibroblasts, and are regulated in these cells by growth factors. Epithelial- 
mesenchymal interactions are an important factor in the progression to cancer, and I 
went on to investigate TIMPs in a gastric cancer cell line, AGS-Gr.
AGS-Gr cells are stably transfected with the CCK2R, and respond to gastrin. 
Immunocytochemistry showed that TIMP-1, -3 and -4 were expressed in this cell 
type. TIMP-1 and -4 were expressed in unstimulated cells and in cells stimulated 
with gastrin; however TIMP-3 expression was very low in unstimulated cells, but 
was induced by gastrin stimulation. This was confirmed by Western blotting, which 
showed that TIMP-3 expression was increased in cells stimulated by gastrin. It has 
previously been shown by gene array in our laboratory that gastrin stimulates TIMP- 
3 expression in these cells (Varro et al. 2002b) and these results support this finding. 
These results also confirm that AGS-Gr cells can be used to investigate TIMP-1, -3 
and -4 expression, and that TIMP-3 expression in these cells is particularly 
interesting as it is the only TIMP influenced by gastrin. In view of this, and also 
from previous results (chapter 1), where TIMP-3 mRNA expression in the gastric 
corpus was increased in H. felis infected Ins-GAS mice, and in patients with PA, I 
decided to focus future experiments on TIMP-3 regulation and function in AGS-Gr 
cells.
I have shown that gastrin induces c-fos expression in AGS-Gr cells, c-fos is part of 
the Fos (c-Fos, Fra-1, Fra-2 and FosB) family of genes, which in combination with 
the Jun (c-Jun, JunB and JunD) families, forms the AP-1 immediate early response 
transcription factor complex (Karamouzis et al. 2007). The AP-1 proteins are usually 
induced in response to a broad spectrum of stimuli including cytokines, growth
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factors, oncogenes and stress signals. This results in the activation of various signal 
transduction pathways to transmit the signal to the nucleus (Young et al. 2006). 
Regulation of AP-1 is usually via changes in transcription of genes encoding AP-1 
subunits, specific interactions of AP-1 proteins with other transcription factors and 
post-translational modification such as phosphorylation by different kinases, such as 
Mitogen-activated protein (MAP) Kinases (Hurd et al. 2002). AP-1 activity plays a 
central role in the control of complex biological processes like cell proliferation and 
differentiation (Angel et al. 1991).
Previous studies in our laboratory have shown that gastrin induces the expression of 
MMP-9 (Wroblewski et al. 2002) and PAI-2 (Varro et al. 2002b) via AP-1 
activation. My results suggest TIMP-3 may be induced by gastrin in a similar 
manner. AP-1 has been shown to be essential for the induction of TIMP-1 gene 
expression by TGF-pi (Hall et al. 2003), to be involved in the induction of TIMP-1 
and -3 in human fibroblasts (Edwards et al. 1996), and TIMP-1 and -2 expression is 
regulated by AP-1 in breast cancer cell lines (Bachmeier et al. 2005).
It has been documented that gastrin stimulates the migration of AGS-Gr cells (Varro 
et al. 2002b, Wroblewski et al. 2002). This suggests that elevated gastrin 
concentration plays an important role in the disruption of normal epithelial 
architecture. TIMP-3 seems to inhibit the gastrin induced migration of AGS-Gr 
cells. This concurs with the MMP inhibitory function of TIMP-3. MMPs, for 
example MMP-7 and -9 are upregulated in hypergastrinaemic conditions (Varro et 
al. 2007, Wroblewski et al. 2002), and the increased expression of TIMP-3 seen 
could be a result of this increased MMP expression. Elevated TIMP-3 expression
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could then act by inhibiting breakdown of the ECM by the MMPs, thus inhibiting 
migration.
In conclusion, this chapter shows that TIMP-1, -3 and -4 are expressed in epithelial 
cells in H. pylori infected gastric mucosa, and TIMP-1 and -3 are expressed in 
gastric myofibroblasts. TIMPs are also expressed in cultured gastric myofibroblasts, 
and their release and/or expression can be upregulated in this cell type by specific 
growth factors.
TIMP-1, -3 and -4 are expressed in gastric cancer cell line AGS-GR, and TIMP-3 
expression is induced by gastrin in this cell type. Gastrin also stimulates the 
expression of c-fos in this cell line. Investigation into the function of TIMP-3 shows 
that it inhibits gastrin induced migration of AGS-Gr cells.
AGS-Gr cells are a useful cell type to investigate the regulation of TIMPs, in 
particular TMP-3, by gastrin.
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Chapter 5 - Cellular mechanisms o f TIMP-3 stimulation by gastrin in AGS-GR cells
5.1 Introduction
In the previous chapter I showed that TIMP-1, -3 and -4 are expressed in the gastric 
cancer cell line AGS-Gr, and TIMP-3 expression is induced by gastrin in this cell 
type. Also gastrin stimulated the expression of c-fos in AGS-Gr cells.
This chapter moves on to investigate the cellular mechanism by which gastrin 
stimulation of TIMP-3 expression occurs in AGS-Gr cells.
In addition to regulating acid secretion, gastrin has other physiological functions 
including an important role in the organisation and maintenance of the gastric 
epithelium. Gastrin upregulates the expression of several proteins important in this 
process, such as Regia (Higham et al. 1999), PAI-2 (Varrò et al. 2002b), MMP-9 
(Wroblewski et al. 2002) and MMP-7 (Varrò et al. 2007). Also gene array data have 
shown that gastrin stimulates TIMP-3 expression in AGS-Gr cells (Varrò et al. 
2002b).
The mechanism by which gastrin stimulates TIMP-3 expression is relevant in order 
to give greater understanding into the role of TIMP-3 in gastrin mediated 
organisation of the gastric epithelium, in normal and pathological conditions.
The aim of this chapter is to investigate the cellular mechanism of gastrin stimulated 
TEMP-3 expression in AGS-Gr cells, to determine if transcriptional activation 
occurs, and to define regions of the TIMP-3 promoter required for responsiveness to 
Gl 7 stimulation.
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5.2 Materials and Methods
5.2.1 Reporter Constructs
All constructs were created using restriction enzyme digests, the DNA fragments of 
interest were cut from 0.8% agarose gels and cleaned using a MinElute Gel 
Extraction Kit (Qiagen). The promoter insert was inserted at appropriate restriction 
enzyme sites (Fig 2 B-E) in pGL4, transformed into competent bacterial cells, and 
purified. The constructs were sequenced before use.
See chapters 2 and 8.1 for detailed conditions for restriction enzyme digests, DNA 
ligation and elution of DNA from agarose gels.
5.2.2 Blunt ending DNA fragments
When truncating the TIMP-3-pGL4 construct to create 1.35Kb, 0.4Kb and 0.25Kb 
constructs, the larger construct was cut using restriction enzymes, and blunt-ended 
before re-ligation.
After carrying out appropriate restriction enzyme digests, the sample was cooled to 
25°C and to this lpl 2.5nM dNTP mix and lpl klenow enzyme (Bioline) were added. 
This reaction was left to proceed for 20 minutes at 25°C and then heated to 75°C for 
20 minutes to inactivate the enzymes.
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5.2.3 Luciferase Reporter Assays
Transfected cells were stimulated in 2ml SFM after washing each well twice with 
SFM. Stimulation with G17 (stock lpM), 50ng/ml EGF (stock 50pg/ml), or lOOnM 
PMA (stock lOOpM) was at 37°C for 8h in all cases apart from time course 
experiment. Here stimulation for 4, 8 and 24h time points were started at the same 
time and cells harvested after the appropriate time. For convenience the 16h 
stimulation was started later and carried out overnight, and cells harvested after 16h. 
In experiments prior to investigation into the effect of G17 concentration on TIMP- 
3-luc activity cells were stimulated with InM G17, following this experiment G17 
stimulation was increased to 5nM. See chapter 2.10 for full details of assays.
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5.3 Results
5.3.1 Creation of TIMP luciferase reporter constructs
Initial luciferase assays were carried out with pXP2 luciferase constructs driven by 
TIMP-1, -3 or -4 promoters. This gave very low luciferase readings and I decided to 
insert the TIMP-1 and -3 promoter inserts into pGL4 luciferase vectors. The pXP2 
vector is 6.2Kb in size, compared to 4.2Kb for pGL4, and the smaller construct size 
can improve transfection efficiency. Moreover pGL4 demonstrates higher expression 
of luciferase than pXP2 since the luc gene is optimized for mammalian expression.
This was achieved by carrying out restriction enzyme digests to remove the TIMP 
promoter inserts from pXP2, and re-ligate the inserts into pGL4.
TIMP-l-pXP2 (obtained from Rod Dimaline) contained 2.6Kb of the TEMP-1 
promoter. This was removed from the plasmid by cutting at Hind III and Bgl II 
restriction enzyme sites. The pGL4 vector was cut sequentially at Bgl II and Hind III 
sites, due to buffer incompatibility. The vector was cut first with Bgl II, the 
linearised plasmid gel-eluted and cut with Hind III. The TIMP-1 promoter fragment 
was then inserted at these sites (Fig 1 A).
TIMP-3-pXP2 (obtained from Rod Dimaline) contained 1.6Kb of the TIMP-3 
promoter. This was removed from the plasmid by cutting at Sail and Bglll restriction 
sites. The pGL4 vector was cut at Xho I and Bgl II restriction sites. Sal I and Xho I 
have compatible ends and the promoter fragment was inserted at the Xho I and Bgl II 
sites in pGL4 (Fig IB).
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pGL4
Bglli TIMP-1
2.6Kb
Hindlll
B
Sail TIMP-3 Xhot Saci B9m 
pXP2 ----------1-------------------------------- 1---------1—
1.6Kb
Xhol TIMP-3 Sacl Bglli 
pGL4 -------1— \-------|------- h
1.6Kb
Fig 1: A. TIMP-1 promoter insert was removed from pXP2 vector at Bgl II and 
Hind III restriction sites. This was inserted into pGL4 at Bgl II and Hind III sites. B. 
TIMP-3 promoter insert was removed from pXP2 vector at Sal I and Bgl II 
restriction sites. This was inserted into pGL4 at Xho I and Bgl II sites.
Fig 2A  shows gel purified 1,6Kb TIMP-3 promoter insert removed from pXP2 using 
restriction enzyme digestion with Sal I and Bgl II, and gel purified empty pGL4 
vector (4.2Kb) digested with Xho I and Bgl II. The fragments were ligated, 
transformed into competent cells and purified using a miniprep kit (Sigma). The 
resulting plasmids were cut using restriction enzymes to see whether they contained
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the expected TIMP promoter inserts. Fig 2B shows TIMP-3-pGL4 constructs, with 
the correct size insert removed by restriction enzyme digest.
Fig 2: A. Gel purified TIMP-3 promoter insert removed from pXP2 (lane 1) and 
empty pGL4 vector (lane 3). B. TIMP-3-pGL4 constructs purified by miniprep and 
cut with Bgl I to remove the TIMP promoter insert. This gives 1.6Kb and 4.2Kb 
fragments. Construct number 1 (lane 1) was sequenced to ensure it contained the 
correct insert in pGL4 prior to large scale plasmid preparation.
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In order to determine regions of the TIMP-3 promoter required for responsiveness to 
G17 stimulation, sequential deletions of the promoter from 1.6-0.25Kb were 
generated. The largest promoter construct (1.6Kb TIMP-3-pGL4) was screened for 
unique restricition enzyme recognition sites within the promoter fragment that could 
be used to generate smaller constructs containing truncated lengths of the TIMP-3 
promoter. The 1.6Kb TIMP-3 promoter was inserted into pGL4 at Xho I and Bgl II 
restriction enzyme sites. Fig 3A shows the restriction enzyme sites available on the 
TIMP-3-pGL4 construct and the TIMP-3 insert. Fig 3B-E show the sites used to 
create the 4 further TIMP-3-pGL4 constructs. The smaller constructs were created by 
cutting the larger construct at the sites indicated. When creating the 0.9Kb construct, 
the cut construct was eluted from an agarose gel, and then re-ligated, as the construct 
was cut twice at Kpn I sites. When creating the other three smaller constructs 
(1.35Kb, 0.4Kb and 0.25Kb) the products of the restriction digest were then run on 
an agarose gel, the required fragment cut out and cleaned, blunt-ended and then the 
construct re-ligated. Fig 4 shows examples of the smaller TIMP-3-pGL4 constructs 
created, after being cut by restriction enzymes to remove part of the TIMP-3 
promoter insert. The required fragment, containing the remaining part of the 
promoter in pGL4 was then cut from the agarose gel and cleaned.
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TIMP-3
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1.35Kb
TIMP-3
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^  l I 0.9Kb
0.4Kb
TIMP-3
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TIMP-3
0.25Kb
Fig 3: A. Restriction enzyme sites on pGL4: (K) Kpn I, (S) Sac I, (N) Nhe I, (X) 
Xho I, (B) Bgl II, (H) Hind III, and positions on TIMP-3 promoter insert: (Ns) Nsi I 
234bp, (K) Kpn I 685bp, (Bs) Bsa I 1171bp, (Sm) Sma I 1244bp and 1538bp, (A) 
Asc I 1347bp, (Bg) Bgl I 1569bp. B-E. Sites used to create truncations of TIMP-3- 
pGL4 construct with sizes of insert. On B-E black represents site used to cut in 
pGL4, red represents site used to cut TIMP-3 promoter insert, construct was blunt- 
ended and re-ligated at these positions. Blue sites are those remaining on the 
plasmid/TIMP-3 insert.
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Fig 4: A. TIMP-3-pGL4 cut with Kpn I to give 0.7Kb and 5.1Kb fragments. The 
5.1Kb fragment was cut from the gel and cleaned before re-ligation. This gave 
0.9Kb of the TIMP-3 promoter in pGL4. B. TIMP-3-pGL4 cut with Bsa I and Nhe I 
to give 1.2Kb and 4.6Kb fragments. The 4.6Kb fragment was cut from the gel and 
cleaned before blunt ending and re-ligation. This gave 0.4Kb of the TIMP-3 
promoter in pGL4.
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5.3.2 Stimulation with G17 and EGF increased expression of TIMP-1, -3and -4 
luc constructs in AGS-Gr cells
Previous results showed that TIMP-1, -3 and -4 are expressed in AGS-Gr cells, and 
that the expression of TIMP-3 is responsive to gastrin in these cells (chapter 2 Fig 6). 
I wanted to progress to investigate the cellular mechanism by which gastrin may 
stimulate TIMP expression in AGS-Gr cells. I first investigated gastrin and EGF 
regulation of luciferase reporter genes driven by TIMP-1, -3 or -4 promoters, in 
AGS-Gr cells. The results showed that the expression of each of the three 
luciferase-reporter constructs increased when cells were stimulated with G17 or 
EGF. For all three TIMPs the increase in stimulation was greater with G17 than with 
EGF (Fig5 A-C).
A B C
Fig 5: Expression of TIMP-1 (A), -3 (B), and -4 (C) luciferase constructs in AGS-
G r  cells with G17 (InM) and EGF (50ng/ml) stimulation for 8h. Representative
results from 2-3 experiments shown. TIMP-l-pGL4, TIMP-3-pGL4 (1.6Kb), TIMP-
4 pXP2 luc constructs used for these experiments. Bars show means from triplicates
normalised to control ± SE. * p< 0.05 ANOVA, relative to control.
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5.3.3 Expression of 1.6kb TlMP-3-Iuc in response to InM G17 is maximal at 16 
hours in AGS-Gr cells
After carrying out initial experiments using TIMP-1, -3 and -4 luciferase constructs, 
which showed that G17 stimulation increased the expression of TIMP-1, -3 and -4 
luciferase constructs in AGS-Gr cells, as I mentioned in the previous chapter, I 
decided to focus on TIMP-3 for future work. Work performed in previous chapters 
(Chapter 2 Figs 6&7) had shown that TIMP-3 expression was increased in AGS-Gr 
cells with G17 stimulation, and that TIMP-3 inhibited G17 induced migration in 
AGS-Gr cells. TIMP-3 had also shown interesting results in myofibroblasts where 
its expression was increased in cultured myofibroblasts from gastric 
adenocarcinoma. IHC showed strong TIMP-3 expression in epithelial and sub- 
epithelial cells from H. pylori positive gastric corpus samples from. Q-PCR showed 
increased expression of TIMP-3 in samples from patients with elevated circulating 
gastrin concentration due to PA. Considering the results from the previous work, and 
the fact that the results from fig 5 confirmed that G17 and EGF stimulation increased 
TIMP-3-luc expression in AGS-Gr cells, I decided to proceed by focusing on TIMP- 
3. (Chapter 2 Figs 1& 2, chapter 1 Fig 4, Bodger et al. 2008)
Before continuing with luciferase assays I carried out a time course experiment for 
G17 stimulation of AGS-Gr cells (Fig 6). This showed that the expression of TIMP- 
3-luc in response to G17 was maximal between 8 and 16h of stimulation. There was 
no difference in expression if stimulation was continued longer than 16h. However 
for convenience, future experiments were carried out with 8h G17 stimulation, as 
this also gave a significant stimulation in TIMP-3-luc activity.
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Fig 6: Time course experiment to investigate G l7 stimulation of TIMP-3-luc. 
Expression was significantly increased after 8h stimulation, and maximal 
stimulation was achieved between 8-16h. There was no difference in expression 
after 16h stimulation. Mean of triplicates shown with values normalised to control 
and expressed as fold increase ± SE. *p<0.05 Student’s t-test. (n=2).
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5.3.4 Expression of 1.6kb TIMP-3-luc in AGS-Gr cells increases progressively 
with G17 concentration from 0.1-5nM
After carrying out a time course experiment for G17 stimulation of TIMP-3-luc 
expression in AGS-Gr cells, I wanted to establish the G17 concentration that gave 
the greatest stimulation of expression.
These experiments showed that the expression of TIMP-3-luc increased 
progressively with increasing concentrations of G17 over the range 0.1-5nM. There 
was no change in expression between 5 and lOnM G17, and O.lnM G17 did not 
result in a significant increase in expression (Fig 7).
Future experiments using this construct were carried out with 5nM G17 stimulation.
0.1 0.5 1 5 10
nM G17
Fig 7: Stimulation of TIMP-3-luc increases progressively with stimulation from 0.5- 
5nM G17. O.lnM G17 does not significantly increase expression (1.2 fold increase) 
and there was no difference in expression between 5 and lOnM G17 stimulation. 
Bars represent means of triplicates expressed as fold increase normalised to control 
± SE. *p<0.05 ANOVA. (n=2).
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5.3.5 Truncation of the TIMP-3 promoter to 1.35 Kb reduces activity in AGS- 
Gr cells
As I mentioned previously the luciferase-reporter construct used contained 1.6Kb of 
the TIMP-3 promoter, and in order to determine regions of the promoter required for 
responsiveness to G17 stimulation, sequential deletions of the promoter from 1.6- 
0.25Kb were generated.
Truncation of the promoter from 1.6Kb to 1.35Kb resulted in a reduction in activity 
with 5nM G17 stimulation. Truncations between 1.35Kb and 0.25Kb did not result 
in any further reduction in activity (Fig 8A).
Examination of the 1.6-1.35Kb region did not reveal any transcription factor binding 
sites of interest, however in the 0-0.25Kb region of the promoter there was a putative 
API transcription factor binding site. Transcription factor binding sites were 
identified using TESS (http://www.cbil.upenn.edu/cgi-bin/tess).
Stimulation of AGS-Gr cells with 5nM G17 did not result in a change in empty 
pGL4 activity (Fig 8B).
118
Chapter 5 - Cellular mechanisms o f TIMP-3 stimulation by gastrin in AGS-GR cells
A
□  control
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Fig 8: A. Truncation of the TIMP-3 promoter from 1.6-1.35Kb showing significant 
decrease in activity compared to 1.6Kb G17 stimulated *p<0.05 ANOVA. B. G17 
stimulation caused no significant change in empty pGL4 activity. Normalised to 
control ± SE. *p<0.05 Student’s t-test. One representative from 3 experiments is 
shown. Bars show means of triplicates expressed as fold increase.
»
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5.3.6 MEK1/2 and PKC inhibitors reduce responses to gastrin stimulation of 
TIMP-3-luc
I had established that stimulation with G17 stimulates the expression of TIMP-3 in 
AGS-Gr cells (chapter 2 fig 6), and of TIMP-3-lue construct. To follow on from this 
I wanted to investigate the cellular mechanism of TIMP-3 stimulation by gastrin in 
AGS-Gr cells.
I found that UO-126, a MEK1/2 inhibitor markedly reduced the gastrin response in 
the large (1.6Kb) TIMP-3-luc construct and virtually abolished it in the 0.25Kb 
TIMP-3-luc construct. PKC inhibitor RO-320432 partially inhibited the effect of 
G17. However PI3K inhibitor LY-294002 had no effect on activity (Fig 9A). A 
similar pattern was seen using the TIMP-3-lue construct containing 0.25Kb of the 
TIMP-3 promoter, although RO-320432 had a greater effect on the response to G l7 
stimulation in this case construct (Fig 9B).
i
120
Chapter 5 - Cellular mechanisms o f TIMP-3 stimulation by gastrin in AGS-GR cells
B
□ control 
5-. ■ 5nM G17
® 4 - w§
£ 3 -  o
£ 1
0
i l l I  Il il 1 rfl li 1 rl 1 i1II ri  n rl
con UO LY
TIMP-31.6Kb
RO con UO LY
TIMP-3 0.25Kb
RO
Fig 9: A. MEK1/2 inhibitor UO-126 markedly reduced the gastrin response in the 
1.6Kb construct. PKC inhibitor RO-320432 partially inhibited the effect of G17. B. 
UO-126 virtually abolished the gastrin response in the 0.25Kb construct. One 
representative of at least 3 experiments is shown. Values are expressed as fold 
increase. Bars show means of triplicates ± SE. *p<0.05 ANOVA representing 
reduction in gastrin response compared to control G17 stimulated.
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5.3.7 PMA stimulates expression of TIMP-3-luc in AGS-Gr cells
Since the PKC inhibitor RO-320432 partially inhibited the response of TIMP-3-luc 
to G l7 stimulation, I decided to investigate whether PMA, an activator of PKC, 
stimulated TIMP-3-lue expression.
I found that PMA did significantly increase the activity of both 1.6Kb and 0.25Kb 
TIMP-3-luc in AGS-Gr cells compared to unstimulated cells. PMA did not, 
however, stimulate TIMP-3 expression to the same extent as stimulation with 5nM 
G17 (Fig 10 A&B), which is consistent with the data obtained using RO-32042.
A B
□control *
QG17
TIMP-31.6Kb TIMP-3 0.25Kb
Fig 10: Stimulation with PMA (lOOnM) stimulated the activity of TIMP-3-luc 
1.6Kb (A) and 0.25Kb (B) constructs. PMA did not stimulate activity to the same 
level as G17. One representative from 2-3 experiments shown. Bars show means of 
triplicates ± SE, expressed as fold increase normalised to control. *p<0.05 ANOVA.
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5.3.8 Co-transfection with c-fos increases the expression of TIMP-3-luc 
compared to a control plasmid
I previously showed by Immunocytochemistry that G17 stimulation of AGS-Gr cells 
induces c-fos expression. This coupled with the fact that MEK inhibitor UO-126 
markedly reduced the gastrin response in the 1.6Kb TIMP-3-luc construct and 
virtually abolished it in the 0.25Kb construct, suggested that stimulation of TIMP-3 
expression by gastrin is regulated by API family members.
Further evidence to support this was gained from the observation that co-transfection 
of AGS-Gr cells with TIMP-3-luc and c-fos resulted in increased luciferase activity 
of the the 1.6Kb and 0.25Kb constructs in otherwise unstimulated cells (Fig 11). The 
increase in activity was comparable to that seen with G17 stimulation (Fig 7). Co­
transfection with TIMP-3 and c-jun had no effect on luciferase activity.
A B
C-jun — + — -  + _
C-fos -  -  + -  -  +
Fig 11: Co-transfection of AGS-Gr cells with TIMP-3-luc and c-fos resulted in 
increased luciferase activity. Representative of 3 experiments is shown. Bars 
represent means of triplicates ± SE, expressed as fold increase normalised to control 
(empty vector). Empty vector used was pCNA3. *p<0.05 ANOVA.
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5.4 Discussion
TIMP-1 and -3 luciferase reporter constructs have been created in pGL4, are active 
in AGS-Gr cells, and luciferase expression is increased by G17. Truncations of the 
TIMP-3 promoter, inserted in pGL4 luciferase vector have been produced, whose 
expression is also increased by G17 stimulation of AGS-Gr cells.
Expression of luciferase from reporter constructs driven by TIMP-1, -3 and -4 
promoters was increased by G17 stimulation of AGS-Gr cells. Transcription of the 
TIMP-3 promoter-reporter construct significantly increased in a dose-dependent 
manner from 0.1-10nM G17. Expression was increased significantly within 4-8h of 
stimulation with InM G17. Previous results from Western blot and 
Immunocytochemistry have shown that G17 stimulation increased the expression of 
TIMP-3 in AGS-Gr cells (chapter 2 Fig 6), although the expression of TIMP-1 and - 
4 were not affected. Because of previous data, the following experiments focused on 
TIMP-3, rather than TIMP-1 or -4.
Epidermal growth factor (EGF) also stimulated the expression of TIMP-1, -3 and -4 
luciferase constructs in AGS-Gr cells. EGF can activate the MAPK pathway to 
induce the expression of many genes, including the gastrin gene (Chupreta et al. 
2000). Gastrin can also induce the expression of members of the EGF family, 
leading to increased proliferation of gastric epithelial cells (Miyazaki et al. 1999, 
Wang et al. 2000).
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Truncating the TIMP-3 promoter from 1.6Kb-1.35Kb caused a significant decrease 
in G17 induced stimulation of expression, however stimulation was not abolished. 
Truncating the promoter between positions 0.25Kb-1.35Kb did not further reduce 
expression. This suggests that a response element exists between 1.35-1.6Kb on the 
TIMP-3 promoter which mediates the stimulation of TIMP-3 expression by gastrin, 
however this is only partially responsible for inducing expression, as stimulation by 
gastrin was not completely abolished. A potential API transcription factor binding 
site exists in the first 0.25Kb of the TIMP-3 promoter. It was not possible to use 
restriction enzyme digests to truncate the promoter in this region, but further work to 
mutate this site would be interesting, in order to investigate the importance of this 
sequence in the response of TIMP-3 expression to gastrin stimulation.
MEK1/2 inhibitor UO-126 significantly reduced, and PKC inhibitor RO-320432 
partially abolished, the G17 induced stimulation of TIMP-3 expression. This 
suggests that gastrin stimulates TIMP-3 expression via activation of the MAPK 
pathway, and that PKC is responsible for some of the gastrin stimulated response.
It has been shown in previous work that The MAPK pathway is an important 
signalling route for the effects of PKC on the activity of AP-1, and this represents an 
important pathway for mediating the effects of gastrin on gene transcription (Davis et 
al. 1993). The MEK kinases activate extracellular signal-regulated kinases (ERKs) in 
response to various factors (Cobb et al. 1995), this upregulates the activity of many 
downstream targets, including transcription factors such as c-fos (Davis et al. 1993). 
In the pancreatic cell line AR4-2J, gastrin activates PKC, stimulates the MAPK
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pathway, activates RhoA, and induces c-fos. (Dabrowski et al. 1997, Stepan et al. 
1999).
It has been found that activation of the gastrin-CCK2 receptor stimulates cell 
migration via signalling mechanisms involving PKC and stimulation of EGF-R and 
the MAPK pathway (Noble et al. 2003)
Hocker et al. (1997) found that ERK-dependent signalling pathways mediated the 
stimulation of the HOC gene by gastrin. Regulation of VMAT2, Egr-1 and TFF1 by 
gastrin in AGS-Gr cells was also found to involve PKC and MAPK-dependent 
pathways (Watson et al. 2001, Raychowdhury et al. 2002, Khan et al. 2003). 
Gastrin-stimulated expression of the CCK2R also seems to be activated in part via 
PKC and MAPK dependent pathways (Ashurst et al. 2008).
Several studies have investigated the involvement of the MAPK pathway in the 
induction of TIMP expression. Activation of the MAPK pathway was found to play 
a key role in the stimulation of TIMP-1 expression and stimulation of proliferation of 
cancer cells, TIMP-3 expression in chondrocytes, TEMP-3 expression in Idiopathic 
pulmonary fibrosis, TIMP-1 expression in human fibrosarcoma cells and in human 
fibroblasts (Porter et al. 2004, Qureshi et al. 2005, Garcia-Alvarez et al. 2006, Kwak 
et al. 2006, Bodet et al. 2007).
The results presented here show that PMA did stimulate the expression of TIMP-3- 
luc, although stimulation was not to such a high level as that seen by G17. This 
concurs with PKC being partially responsible for activating TIMP-3 expression in 
response to gastrin stimulation.
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Co-transfection of AGS-Gr cells with c-fos and TIMP-3-luc increased luciferase 
activity, which supports the view that gastrin stimulates TIMP-3 expression in AGS- 
Gr cells via activation of API. Further support for this comes from the fact that 
Immunocytochemistry showed that G17 stimulation of AGS-Gr cells induced c-fos 
expression (chapter 2 Fig 7).
Taken together the results from this chapter suggest that gastrin stimulates the 
MAPK pathway to increase TIMP-3 transcription via API, which results in 
inhibition of MMPs by TIMP-3, and contributes to remodelling of the ECM, which 
is important in a range of pathological conditions, such as inflammation (Fig 12).
MMP Inhibition
i  Migration 
ECM Remodelling
Fig 12: Representation of control of TIMP-3 expression by gastrin. Gastrin acts via 
MAPK pathway, activating API, resulting in TIMP-3 expression. This may involve 
activation by PKC. TIMP-3 has roles in MMP inhibition, and roles which may be 
independent of MMP inhibition, such as inhibition of migration. This has a role in 
ECM remodelling.
Gastrin
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6.1 Major Findings
TIMP-1 and -3 mRNA expression increases in the corpus of Ins-GAS mice six 
months after infection with Helicobacter felis, compared to uninfected mice (Ch 3 
Fig 3). In human corpus biopsies from patients with pathologically high circulating 
gastrin due to PA, the mRNA expression of all four TIMPs increased significantly, 
compared to patients with normal gastrin concentrations (Ch 3 Fig 4). When two PA 
patients were treated with octreotide, a somatostatin analogue, for 72h both patients 
showed a reduction in TIMP expression. Moreover after undergoing an antrectomy 
to permanently reduce the gastrin drive TEMP expression was reduced by almost 
50% in two further patients (Ch 3 Fig 5).
Western blotting performed on whole cell lysates from cultured gastric 
myofibroblasts showed that all four TIMPs were expressed in patients with gastric 
adenocarcinoma (Ch 4 Fig 2), and TIMP-1, -2 and -4 expression was increased in 
myofibroblasts derived from the tumour, compared to adjacent normal tissue. TIMP- 
3 was expressed to a similar level in both sets of cells.
Stimulation of cultured gastric myofibroblasts, derived from normal gastric corpus 
mucosa, with HGF and TGF-P showed an increase in protein abundance of TIMP-1 
in the medium. Stimulation with HGF, PDGF and TGF-P increased the abundance of 
TEMP-3 in whole cell lysates (Ch 4 Figs 4 & 5).
TEMP-1, -3 and -4 were expressed in the gastric cancer cell line AGS-Gr, and 
stimulation of these cells with G17 resulted in an increase in TIMP-3 expression, but 
did not alter TIMP-1 or -4 expression (Ch 4 Fig 6). Stimulation with 5nM G17 for 2h
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also induced expression of the immediate early response gene c-fos in the nuclei of 
AGS-Gr cells (Ch 4 Fig 7).
Incubation of AGS-Gr cells with recombinant TIMP-3 inhibited gastrin-induced 
migration, and knocking down TIMP-3 expression with siRNA resulted in an 
increase in migration of gastrin stimulated AGS-Gr cells (Ch 4 Fig 8).
Stimulation with G17 increased the expression of a TIMP-3 luciferase-reporter 
construct in AGS-Gr cells. UO-126, a MEK1/2 inhibitor markedly reduced and 
PKC inhibitor RO-320432 partially inhibited the gastrin response of the TIMP-3-luc 
construct (Ch 5 Fig 9).
Co-transfection of AGS-Gr cells with TIMP-3-luc and c-fos resulted in increased 
luciferase activity to a comparable level to that seen with G17 stimulation (Ch 5 Fig 
11).
6.2 Regulation of TIMP expression in the gastric mucosa of humans 
and a mouse model of hypergastrinaemia
Six months following H. felis infection, Ins-GAS mice showed increased expression 
of TIMP-1 and -3 mRNA in the gastric corpus, compared to non-infected control 
mice. Three months following H. felis infection there was no difference in TIMP 
expression. Preliminary data investigating TIMP expression with H. pylori infection 
in humans showed an increase in the expression of TIMP-1, -3 and -4, therefore the
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results obtained in Ins-GAS mice are interesting as they correlate with those from 
human samples. In both humans and mice Helicobacter infection induces 
overexpression of TIMP-1 and -3, and the Helicobacter infected Ins-GAS mouse can 
therefore be used as an animal model for investigating TIMP expression in response 
to infection.
Ins-GAS mice have raised plasma gastrin concentrations and develop hyperplasia, 
similar to that seen in humans with CAG; older mice have an increased tendency to 
develop gastric cancer which is accelerated with Helicobacter infection (Wang et al. 
1996, Wang et al. 2000). Gastrin levels in the Ins-GAS mouse samples used were 
similar in the control and infected mice. This suggests that in these experiments 
inflammation due to H. felis infection rather than hypergastrinaemia was responsible 
for the increase in TIMP expression.
Increased TIMP expression with Helicobacter infection may occur due to a 
corresponding increase in MMP expression. MMP expression is known to increase 
in response to inflammation associated with H. pylori infection. This contributes to 
ECM remodelling, which in some cases leads to gastric cancer (Wroblewski et al. 
2003, Hemers et al. 2005, McCaig et al. 2006). TIMPs also have roles independent 
of MMP inhibition (Lambert et al. 2004), and this could also have important 
consequences in increased TIMP expression with H. pylori infection.
The expression of TIMP 1-4 mRNA increased significantly in gastric biopsy samples 
from patients with PA, compared to samples from patients with normal gastrin levels 
(<30pM). Patients with PA develop extremely high circulating gastrin levels, 
potentially rising to 2000pM, over a period of many years. I found no significant 
increase in TEMP expression between patients with normal gastrin levels and those
130
Chapter 6 - Discussion
with elevated gastrin due to conditions other than PA, such as treatment with proton 
pump inhibitors (PPIs). PPIs are not likely to result in such high gastrin levels as 
those seen in PA, and this would occur over a shorter period of time, suggesting that 
very high gastrin levels, or that elevated gastrin over a very long period of time is 
required to increase TIMP expression.
In PA, ECL cell hyperplasia is common (Jensen 2002), in 5-10% of cases this 
progresses to the development of gastric carcinoid tumours (Bordi et al. 1991, Bordi 
et al. 1995). Large carcinoid tumours (>2cm) carry a significant risk of metastasis 
(Thomas et al. 1995). Antrectomy removes the gastrin secreting G-cells located in 
the antrum, and is often used as a treatment for ECL tumours. Octreotide is a 
somatostatin analogue and is known to decrease plasma gastrin levels and reduce 
ECL cell number in patients with CAG (Bordi et al. 1993, Ferraro et al. 1996). An 
octreotide suppression test, as described by Higham et al. (1998), can be used to 
determine whether large carcinoid tumours are responsive to gastrin, and thus 
whether antrectomy, rather than total gastrectomy, would be an appropriate treatment 
for large ECL carcinoid tumours. In samples from PA patients after octreotide 
infusion, and also pre and post antrectomy, TIMP overexpression due to 
hypergastrinaemia was reduced both after the octreotide suppression test and 
antrectomy. This suggests that upregulation of TIMP expression due to PA can be 
reversed after long term reduction of gastrin secretion by antrectomy.
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6.3 The responsiveness of TIMP expression
Immunohistochemistry confirmed that TIMPs are expressed in a variety of cell types 
in H. pylori positive gastric mucosa. TIMP-1, -3 and -4 were expressed strongly in 
glandular epithelial cells, TIMP-3 and -4 were expressed in inflammatory cells, but 
TIMP-1 showed only weak positivity in these cells. TIMP-3 showed strong staining 
in myofibroblasts, while TIMP-1 showed weaker expression in myofibroblasts. 
TIMP-4 was localised exclusively in epithelial cells and not seen in myofibroblasts. 
This difference in cellular localisation between the individual TIMPs suggests 
varying roles for each TEMP in the gastric mucosa, and that the expression of each is 
influenced in a different way by H. pylori infection.
Western immunoblotting and Immunocytochemistry confirmed that TIMP-1 and -3 
are expressed in cultured myofibroblasts from the site of a gastric adenocarcinoma 
and from adjacent macroscopically normal tissue. These can therefore be used to 
investigate TIMP expression and function in a sub-epithelial cell type.
Stimulation of myofibroblasts with HGF and TGF-p caused an increase in TIMP-1 
abundance in the culture medium from these cells. Stimulation with HGF, PDGF and 
TGF-P stimulated TIMP-3 expression in whole cell lysates from myofibroblasts, 
showing that TEMP expression in myofibroblasts can be stimulated by growth 
factors. TGF-p can contribute to cancer progression by promoting tumour cell 
differentiation and metastasis (Moustakas et al. 2002), increased TIMP expression in 
myofibroblasts in response to TGF-P could be due to their roles in inhibition of ECM 
breakdown, TEMPs have also been found to promote metastasis in some tissues
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(Baker et al. 2002). TGF-p is also involved in fibrosis, e.g in the kidney (Moustakas 
& Heldin 2007), and this could be a factor in TIMP upregulation in response to this 
growth factor. TGF-P induced TIMP-1 expression in cultured intestinal 
myofibroblasts and myometrial smooth muscle cells, and induced TIMP-3 
expression in lung fibroblasts and human chondrocytes (McKaig et al. 2003, Qureshi 
et al. 2005, Garcia-Alvarez et al. 2006). TGF-P signalling in stromal myofibroblasts 
induces expression of HGF, and this promotes enhanced proliferation and invasion 
(Moustakas & Heldin 2007). PDGF has roles in promoting cell migration and 
survival (Tallquist et al. 2004). TIMPs have roles in inhibiting cell migration 
(Anand-Apte et al. 1996, Oh et al. 2004) and inhibiting apoptosis (Jiang et al. 2002), 
which could explain the increase in their expression in response to PDGF. PDGF is 
found to induce TIMP-1 expression in human dermal fibroblasts (Jinnin et al. 2005).
It is interesting that the expression of the different TIMPs varies in the gastric 
myofibroblasts. TIMP-1 was upregulated by growth factors in media from stimulated 
myofibroblasts while TIMP-3 was upregulated by growth factors in the cell lysates 
and not in medium. This could be due to the TIMPs having different roles and being 
regulated differently in this cell type. TIMP-3, unlike the other TIMPs, is tightly 
bound to the extracellular matrix and thus is not secreted like the other TIMPs 
(Woessner 2001), and this could explain why it was not seen in culture medium.
Epithelial-mesenchymal interactions are an important factor in the progression to 
cancer, and I went on to investigate TIMP expression in a gastric cancer cell line, 
AGS-Gr, which are stably transfected with the CCK2R, and respond to gastrin. 
TIMP-1, -3 and -4 are expressed in this cell type. TIMP-1 and -4 were expressed to 
similar level in unstimulated cells and in cells stimulated with G17; however TIMP-
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3 expression was very low in unstimulated cells, but was induced by G17. This 
supports previous findings from our laboratory where gene array showed stimulation 
of TIMP-3 expression in AGS-Gr cells by gastrin (Varro et al. 2002b). These 
results showed that TIMP-3 expression in these cells is particularly interesting as it is 
the only TIMP influenced by gastrin.
Expression of luciferase from reporter constructs driven by TIMP-1, -3 and -4 
promoters was increased by G17 stimulation of AGS-Gr cells. Transcription of the 
TIMP-3 promoter-reporter construct significantly increased in a dose-dependent 
manner from 0.1-10nM G17. Expression was increased significantly within 4-8h of 
stimulation with InM G17. Epidermal growth factor (EGF) also stimulated the 
expression of TIMP-1, -3 and -4 luciferase constructs in AGS-Gr cells. EGF can 
activate the MAPK pathway to induce the expression of many genes, including the 
gastrin gene (Chupreta et al. 2000). Gastrin can also induce the expression of 
members of the EGF family, leading to increased proliferation of gastric epithelial 
cells (Miyazaki et al. 1999, Wang et al. 2000).
Results from Western immunoblotting and Immunocytochemistry showed that G17 
stimulation increased the expression of TIMP-3 in AGS-Gr cells, although the 
expression of TIMP-1 and -4 were not affected. G17 also stimulated the expression 
of a TIMP-3 luciferase construct in AGS-Gr cells. Also TIMP-3 mRNA expression 
in the gastric corpus was increased in H. fells infected Ins-GAS mice, and in patients 
with PA. In view of the results obtained at this stage, I decided to focus future 
experiments on TIMP-3 regulation and function in AGS-Gr cells.
Results from migration assays suggest that TIMP-3 inhibits the gastrin induced 
migration of AGS-Gr cells. It has been documented that gastrin stimulates the
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migration of AGS-Gr cells (Varro et al. 2002b, Wroblewski et al. 2002), suggesting 
that elevated gastrin concentration plays an important role in the disruption of 
normal epithelial architecture. The inhibition of migration by TIMP-3 concurs with 
its MMP inhibitory function. MMP-7 and -9 are found to be upregulated in 
hypergastrinaemic conditions (Varro et al. 2007, Wroblewski et al. 2002), and the 
increased expression of TIMP-3 seen could be in response to increased MMP 
expression. Elevated TIMP -3 expression could then act by inhibiting breakdown of 
the ECM by the MMPs, thus inhibiting migration.
6.4 The cellular mechanism of TIMP expression
Expression of luciferase from a reporter construct driven by the TIMP-3 promoter is 
increased by G17 stimulation of AGS-Gr cells. Truncating the TIMP-3 promoter 
from 1.6Kb-1.35Kb caused a significant decrease in G17 induced stimulation of 
expression, however stimulation was not abolished. This suggests a response 
element exists in this region of the TIMP-3 promoter, which mediates the gastrin 
stimulation of TIMP-3 expression. Stimulation by gastrin was not completely 
abolished and this indicates that this response element is only partially responsible 
for inducing expression. A potential API transcription factor binding site was 
located in the first 0.25Kb of the TIMP-3 promoter.
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A MEK1/2 inhibitor significantly reduced, and a PKC inhibitor partially abolished, 
the G17 induced stimulation of TIMP-3 expression. This suggests that gastrin 
stimulates TIMP-3 expression via activation of the MAPK pathway, and that PKC is 
responsible for some of the gastrin stimulated response.
Previous work has shown that the MAPK pathway is an important signalling route 
for the effects of PKC on the activity of AP-1, and this represents an important 
pathway for mediating the effects of gastrin on gene transcription (Davis et al. 1993). 
Activation of the CCK2R stimulates cell migration via signalling mechanisms 
involving PKC and stimulation of EGF-R and the MAPK pathway (Noble et al. 
2003). Regulation of VMAT2, Egr-1 and TFF1 by gastrin in AGS-Gr cells was also 
found to involve PKC and MAPK-dependent pathways (Watson et al. 2001, 
Raychowdhury et al. 2002, Khan et al. 2003). Gastrin stimulated expression of the 
CCK2R also seems to be activated in part via PKC and MAPK dependent pathways 
(Ashurst et al. 2008).
Activation of the MAPK pathway was found to play a key role in the stimulation of 
TIMP-1 expression in human fibrosarcoma cells and in human fibroblasts, and also 
TIMP-3 expression in chondrocytes and in idiopathic pulmonary fibrosis (Porter et 
al. 2004, Qureshi et al. 2005, Garcia-Alvarez et al. 2006, Kwak et al. 2006, Bodet et 
al. 2007).
PMA was shown to stimulate the expression of the TIMP-3 luciferase reporter 
construct, although not to the same level as that seen by G17 stimulation. This agrees 
with PKC being partially responsible for activating TIMP-3 expression in response 
to gastrin stimulation.
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My results showed that gastrin stimulates the expression of c-fos in AGS-Gr cells. 
c-fos is part of the Fos family of genes, which in combination with the Jun families, 
forms the AP-1 immediate early response transcription factor complex (Karamouzis 
et al. 2007). The AP-1 proteins are induced in response to a broad spectrum of 
stimuli including cytokines, growth factors, oncogenes and stress signals (Young et 
al. 2006), and play a central role in the control of complex biological processes like 
cell proliferation and differentiation (Angel et al. 1991). AP-1 can be regulated via 
the MAPK pathway (Hurd et al. 2002).
Previous studies in our laboratory have shown that gastrin induces the expression of 
MMP-9 (Wroblewski et al. 2002) and PAI-2 (Varro et al. 2002b) via AP-1 
activation. My results suggest TIMP-3 may be induced by gastrin in a similar 
manner. AP-1 has been shown to be essential for the induction of TIMP-1 gene 
expression by TGF-pl (Hall et al. 2003), to be involved in the induction of TIMP-1 
and -3 in human fibroblasts (Edwards et al. 1996), and TEMP-1 and -2 expression is 
regulated by AP-1 in breast cancer cell lines (Bachmeier et al. 2005). In the 
pancreatic cell line AR4-2J, gastrin activates PKC, stimulates the MAPK pathway, 
activates RhoA, and induces c-fos. (Dabrowski et al. 1997, Stepan et al. 1999).
Co-transfection of AGS-Gr cells with c-fos and TIMP-3-luc increased luciferase 
activity, which, in addition to the finding that G17 stimulation of AGS-Gr cells 
induced c-fos expression, supports the view that gastrin stimulates the MAPK 
pathway to increase TIMP-3 transcription via API, which results in inhibition of 
MMPs by TIMP-3, and contributes to remodelling of the ECM.
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Stimuli e.g Gastrin
Growth Factors
MMP inhibition 
ECM Remodelling 
|  Migration
Fig 1: Summary of findings. Stimuli such as gastrin, growth factors and H. p y lo r i  
infection stimulate epithelial cells. Epithelial and mesenchymal cells communicate 
with each other via epithelial-mesenchymal signalling. Expression of TIMPs is 
upregulated by stimuli in epithelial and mesenchymal cells e.g. myofibroblasts. 
Signalling e.g. by gastrin activates the MAPK pathways, PKC being partially 
responsible for this activation. Expression of c-fos is stimulated in the nucleus, 
which forms part of the API transcription factor complex, this leads to gene 
transcription, including TIMPs. TIMPs inhibit MMP activity and migration which 
contribute to ECM remodelling.
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6.5 Future work
-  A potential API transcription factor binding site exists in the first 0.25Kb of 
the TIMP-3 promoter used to drive luciferase expression in reporter 
constructs. It was not possible to use restriction enzyme digests to truncate 
the promoter in this region, but further work to mutate this site would be 
interesting, in order to investigate the importance of this sequence in the 
response of TIMP-3 expression to gastrin stimulation.
-  Expression of luciferase activity by a reporter construct driven by a TIMP-3 
promoter has been used to investigate the response of TIMP-3 to gastrin in 
AGS-Gr cells. TIMP-1 and -4 are also expressed by this cell line, and 
luciferase promoter constructs driven by these promoters exist. Initial results 
showed that the expression of these constructs was stimulated by G17 in 
AGS-Gr cells. Further investigation into the regulation of TIMP-1 and -4 in 
response to gastrin would be interesting.
-  It was found that TIMP-3 inhibited gastrin induced migration of AGS-Gr 
cells, futher investigation into the function of TIMP-3 in AGS-Gr cells 
would be interesting, for example by performing invasion or proliferation 
assays.
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8.1 Appendix 1
8.1.1 Restriction enzymes used and reaction conditions
Enzyme Company Buffer
Temperature
(°C)
BSAY/N
Hindlll Sigma NEB 2 37 N
Nhel NEB NEB 2 37 Y
Xhol Sigma NEB 2 37 Y
Kpnl Sigma NEB 1 37 Y
Bglll Sigma Sigma SM/ NEB 3 37 N
Sail Sigma Sigma SH 37 Y
Bgll Sigma Sigma SH/NEB 3 37 N
AscI NEB NEB 4 37 N
Nsil NEB NEB 3 37 N
Bsal NEB NEB 3 50 N
Smal Sigma NEB 4 25 N
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8.1.2 Double restriction enzymes digest reaction conditions.
Enzyme 1 Enzyme 2 Buffer Temperature
(°C)
BSA(Y/N)
Bglll Sail Sigma SH 37 N
Bglll Xhol Sigma SH 37 N
Hindlll Sail NEB 2 37 N
Hindlll Xhol NEB 2 37 Y
Asci Miel NEB 4 37 Y
Miel Nsil NEB 2 37 N
Bsal Miei NEB 4 37 for lh 
50 for lh
N
Bglll Kpnl NEB 2 37 Y
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8.2.1 Composition of QIAGEN buffers used for purification of plasmid DNA 
and gel elution of DNA
QIAGEN 
Buffer PI
50mM Tris-Cl pH8, lOmM Na2EDTA in 100pg/ml RNase A.
Buffer P2
200mM NaOH, 1% SDS (w/v).
Buffer P3
1M potassium acetate pH5.5.
Buffer QBT
750mM NaCl, 50mM MOPS pH7, 15% isopropanol (v/v), 0.15% Triton X-100
(v/v).
Buffer QC
8.2 Appendix 2
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1M NaCl, 50mM MOPS pH 7,15% isopropanol (v/v).
Buffer QF
1.25M NaCl, 50mM Tris-Cl pH8.5, 15% isopropanol (v/v).
Buffer EB
10 mM Tris-Cl, pH 8.5
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8.3 Appendix 3
Q-PCR primer (F & R) and probe (T) sequences
Mouse
TIMP-1
F: 5’-CCAGAACCGCAGTGAAGAGTT 
R: 5 ’ - A AGCT GC AGGC ACT GAT GT G 
T: 5’ -CTCATCACGGGCCGCCTAAGGA
TIMP-3
F: 5 ’ - GGC ACTCT GGTCT AC ACT ATT AAGC A 
R: 5 ’ -C AGAGGCTT CCG AGAG A AT GT 
T: 5’-CGAGGCTTCAGTAAGATGCCCCACGT
TIMP-4
F: 5 ’ -GCC ACTCGGCTCT AGT GAT ACG
R: 5 ’ -GAGT GT C AGGGT CTTT GC
T: 5 ’ -CC AAA AT ATCC AGT GAG AAGGT AGT CCCT GCC
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Human
TIMP-1
F: 5 ’ -GCTGACATCCGGTTCGTCTAC 
R: 5’- GTTGTGGGACCTGTGGAAGTATC 
T: 5’ - CCCCCGCCAT GG AG AGT GTCTG
TIMP-2
F: 5 ’ -CCT GAACC AC AGGT ACC AG AT G 
R: 5 ’ - AGG AG AT GT AGCGG AT C A 
T: 5’-AGTGCAAGATCACGCGCTGCCC
TIMP-3
F: 5 ’ -TT CGGTT ACCCT GGCT ACC A 
R: 5’-GCAGTAGCCGCCCTTCTG 
T: 5’-TCCAAACACTACGCCTGCATCCGG
TIMP-4
F: 5 ’ -C ACCCT C AGC AGC AC ATCT G 
R: 5’-GGCCGGAACTACCTTCTCACT 
T: 5 ’ - ACTCGGC ACTT GT GATT CGGGCC
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8.4 Appendix 4
8.4.1 Primary Antibodies used for Western Blotting
Antibody Type Dilution company
Timp-1 6D11 Mouse anti human 1:100 RDI
Timp-1 AB8112 Rabbit anti human 1:1000 Chemicon
Timp-2 4H11 Mouse anti human 1:1000 RDÏ
Timp-2 AB 19078 Rabbit anti human 1:200 RDI
Timp-2 AB8107 Rabbit anti human 1:1000 Chemicon
Timp-3 Cl Mouse anti human 1:1000 RDI
Timp-3 AB802 Rabbit anti human 1:2000 Chemicon
Timp-3 MAB3318 Mouse anti human 1:1000 Chemicon
Timp-4 AB816 Rabbit anti human 1:1000 Chemicon
8.4.2 Secondary Antibodies
Antibody Dilution company
Goat Anti Mouse 1:5000 Sigma
Goat Anti Rabbit 1:10,000 Pierce
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8.5 Appendix 5
Antibodies used for Immunocytochemistry
Antibody Type Dilution company
Timp-1 Cl Mouse anti human 1:100 RDI
Timp-1 6D11 Mouse anti human 1:100 RDI
Timp-2 4H11 Mouse anti human 1:200 RDI
Timp-3 Cl Mouse anti human 1:20 RDI
Timp-3 AB802 Rabbit anti human 1:200 Chemicon
Timp-3 MAB3318 Mouse anti human 1:100 Chemicon
Timp-3 SC-6838 Goat anti human 1:100 Santa Cruz
Timp-4 RB-1542-R7 Rabbit anti human Neat Stratech
Timp-4 AB816 Rabbit anti human 1:200 Chemicon
anti-fos 554156 Mouse anti human 1:250 PharMingen
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8.6 Appendix 6
Map of pGL4.10 luciferase vector 
(obtained from www.promega.com)
Synthetic pofy(A) 
stgnalrtranscriplional 
pause site 
(for background 
reduction)
Ggi USI 1 1 
Acc65 i 
Kpnl 
EcolCR I 
Sac I 
M ie l 
Xho I 
EcoR V 
Bgll I 
Bq! I/Stf 1 
Hind III
SV40 late 
poly(A) signal
9
15
18
24
26
28
34
42
47
60
66
%
<vrN
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